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Ionizing radiation (IR) and chemotherapy are standard of care treatments for glioblastoma 
(GBM) patients and both result in DNA damage, however, the clinical efficacy is limited due to 
therapeutic resistance. We identified a mechanism of such resistance mediated by 
phosphorylation of PTEN on tyrosine 240 (pY240-PTEN) by FGFR2. pY240-PTEN is rapidly 
elevated and bound to chromatin through interaction with Ki-67 in response to IR treatment and 
facilitates the recruitment of RAD51 to promote DNA repair. Blocking Y240 phosphorylation 
confers radiation sensitivity to tumors and extends survival in GBM preclinical models. Y240F-
Pten knock-in mice showed radiation sensitivity. These results suggest that FGFR-mediated 
pY240-PTEN is a key mechanism of radiation resistance and is an actionable target for 
improving radiotherapy efficacy. 
 
KEY WORDS: PTEN, tyrosine phosphorylation, FGFR2, GBM, ionizing radiation (IR), DNA 
damage 
SIGNIFICANCE  
Although Ionizing radiation (IR) has been applied as standard of care treatment for GBM, 
therapeutic resistance remains a significant barrier for successful outcome. Understanding the 
underlying mechanisms of this resistance will aid in the development of improved therapeutic 
strategies. Here we show phosphorylation of PTEN at tyrosine 240 (pY240) promotes efficient 
DNA repair and tumor cells with detectable pY240-PTEN survive therapies that rely on 
generation of DNA damage. Blocking Y240 phosphorylation confers radiation sensitivity to 
tumors and extends survival in GBM preclinical models. We propose that pY240-PTEN status in 
tumors could predict IR response and strategies blocking this specific PTEN modification could 
sensitize tumors to IR and improve survival of patients with GBM and potentially other cancers. 
INTRODUCTION 
The phosphatase and tensin homolog gene (PTEN) encodes a protein that antagonizes the 
Phosphatidylinositol-3-kinase (PI3K) pathway as a lipid phosphatase. PTEN is the most 
frequently altered tumor suppressor gene in GBM (Cancer Genome Atlas Research, 2008; 
Furnari et al., 2007) and its loss or mutation has been implicated as a cause of resistance to 
therapies such as tyrosine kinase inhibitors (TKIs) due to permissive activation of the AKT 
pathway. However, depletion of PTEN has also been shown to sensitize tumor cells to therapies 
that rely on DNA damage, such as ionizing radiation (Mansour et al., 2018; McCabe et al., 
 2015). While investigations of PTEN have largely focused on its canonical role as a lipid 
phosphatase, recent studies suggest that PTEN has functions independent of its cytoplasmic 
phosphatase activity, including poorly characterized nuclear functions (Milella et al., 2015).  
Glioblastoma (GBM) is the most lethal brain tumor occurring in adults and its treatment has 
been largely unsuccessful. Ionizing radiation (IR) is one of the few therapies with demonstrated 
clinical efficacy for patients with GBM (Bao et al., 2006) and about 50% of all cancer patients 
will receive radiotherapy during their course of treatment (Begg et al., 2011). Unfortunately, the 
efficacy of IR for GBM patients is modest, at best, due to radio-resistance of the tumor, the 
underlying mechanisms of which remain poorly characterized. The principal biological effect of 
radiotherapy is to kill rapidly proliferating cancer cells by inducing DNA damage beyond cellular 
capacity for repair, including DNA single strand breaks (SSBs), double strand breaks (DSBs), 
DNA termini modifications, and cross-linked DNA (Gulston et al., 2002). DSBs are considered to 
be the most harmful form of DNA damage in most cases, failure to repair DSBs can trigger cell 
death. The repair of DSBs is an orchestrated process that requires the prompt response of 
many factors that assemble the proper repair machinery at the sites of damage. Any alterations 
in tumor cells that favor DNA repair efficiency would be predicted to cause resistance to 
therapies that rely on DNA damage.  
Accumulating evidence has shown that PTEN can also be found in the nucleus where it is 
involved in the regulation of DNA damage repair, chromosome stability, and cell cycle 
progression mediated by phosphatase-independent activity (Milella et al., 2015; Shen et al., 
2007). PTEN function can be affected not only by genetic mutations but also by 
posttranslational modifications, such as SUMOylation, phosphorylation, ubiquitination oxidation, 
and acetylation (Leslie et al., 2016; Wang and Jiang, 2008). We have previously demonstrated 
that phosphorylation of PTEN on tyrosine 240 (pY240-PTEN) is commonly found in GBM 
samples obtained from patients treated with standard of care therapy, temozolomide and IR, 
and detection of this posttranslational modification is associated with shortened survival (Fenton 
et al., 2012). Because DNA damage is the principal objective of standard of care therapy, in this 
study, we examined if pY240-PTEN functionally mediates therapeutic resistance by regulating 
DNA repair. 
Results 
FGFR2-mediated phosphorylation of PTEN tyrosine 240 protects cells from DNA damage 
by facilitating DNA repair 
 To study the potential involvement of PTEN in DNA damage repair in GBM, we first examined 
nineteen clinical GBM samples (Table S1) for the presence of pY240-PTEN and phospho-
Histone 2A.X (pH2AX), a marker of DNA double strand breaks (DSBs). An inverse correlation 
was found between the two (Figure 1A), suggesting that pY240-PTEN may affect the DNA 
repair process. Based on previous data, PTEN Y240 phosphorylation is promoted by FGFRs 
and Src family kinases (Fenton et al., 2012). We conducted in vitro kinase reactions using wild 
type PTEN and a tyrosine to phenylalanine non-phosphorylatable control (Y240F-PTEN) and 
examined PTEN phosphorylation using typical and modified SDS PAGE (Phos-Tag) protein 
gels. Compared with Src, FGFR2 preferentially phosphorylates PTEN at Y240 over other sites 
since Y240F-PTEN showed limited phosphorylation detected by pan-anti-phosphotyrosine 
antibodies (Figure 1B, S1A). Given the reduction of two phosphorylated bands by Y240F 
mutation (Figure 1B, 4G10), this result suggests pY240 might be required for the 
phosphorylation of the other site. Furthermore, rather than working indirectly via downstream 
effectors, FGFR2 directly phosphorylated Y240, as shown by FGFR2 mutants defective for 
downstream signaling (Mohammadi et al., 1996) retaining the ability to induce pY240-PTEN, 
whereas a kinase dead FGFR2 mutant failed to do so (Figure 1C). To determine whether these 
results are clinically pertinent, we tested 43 patient-derived glioma stem cell lines (GSCs) for 
PTEN and FGFR2 expression and their radiosensitivity. GSCs with low PTEN expression were 
found to be more radiosensitive, and in concordance with our data, those with high PTEN and 
FGFR2 expression also exhibited more PTEN nuclear localization (Figure S1B) and were 
relatively radioresistant (Figure 1D and Table S2).  
To investigate if pY240-PTEN was responsible for enhancing DNA repair, as suggested by 
the above findings, different cell systems were utilized in this study (Table S3). FGFR2 was 
expressed in the U87 (PTEN null) glioma cell line that had been reconstituted with WT- or 
Y240F-PTEN (Figure S1C), followed by IR treatment.  When compared with Y240F-PTEN 
expressing cells (Figure 1E), vector control cells or cells lacking FGFR2 (Figure S1D-E), the 
presence of FGFR2 in cells expressing WT-PTEN resulted in phosphorylation at Y240 and 
resistance to IR, as indicated by clonogenic survival (Figure 1E, S1D-E).  Furthermore, using 
neutral comet assays, we found less DNA damage in WT-PTEN cells compared with Y240F-
PTEN cells at 24 hr after IR (Figure 1F). Similarly, this effect was dependent on FGFR2-
mediated phosphorylation of PTEN at Y240 as no significant difference was detected between 
the two cells in the absence of the receptor (Figure S1F). 
 We next investigated whether pY240-PTEN affected DNA damage response. In the presence 
of FGFR2, while pH2AX downstream of ATM activation (pATM) was transiently induced in WT-
PTEN cells, sustained pH2AX occurred up to 24 hr after IR in Y240F-PTEN cells, suggesting 
cells lacking pY240-PTEN harbor defects in DNA repair. The initiation of DNA damage response 
was unaltered since ATR and ATM were similarly activated in WT- and Y240-PTEN cells 
(Figure 1G). Expressing a kinase dead FGFR2 along with WT- or Y240F-PTEN did not induce a 
difference in pH2AX after IR (Figure S1G). These results were recapitulated by assessment of 
JH2AX in situ showing foci were induced in both cells and were largely resolved in WT-PTEN 
cells by 24 hr but not in Y240F-PTEN, suggesting the persistence of unrepaired DSBs (Figure 
1H). We next assessed whether pY240-PTEN interfaced with homologous recombination (HR) 
or non-homologous end joining (NHEJ), the two major mechanisms of DNA repair. While no 
difference in total RAD51 protein levels between the two cells was detected (Figure 1G), Y240F-
PTEN cells showed a reduction in RAD51 recruitment to DNA damage sites post-IR compared 
to WT-PTEN cells (Figure 1I). Supporting a key role for pY240-PTEN in HR, more efficient HR-
mediated repair occurred in WT-PTEN cells compared to Y240F-PTEN cells in a Traffic Light 
Reporter (TRL) assay (Figure S1H), while NHEJ-mediated repair was equivalent for both cells. 
To determine if the formation of single strand DNA at DSBs, which serves as a platform for 
RAD51 loading, was differently affected, we monitored RPA32 foci formation (Figure S1I) and 
bromodeoxyuridine (BrdU) incorporation (Figure S1J) and found no difference between WT- and 
Y240F-PTEN cells. Taken together, these results suggest that pY240-PTEN promotes HR-
mediated DSB repair by facilitating RAD51 filament formation or stabilization (Figure 1J).  
pY240-PTEN confers resistance to DNA damage in GBM stem-like cells  
We next examined GBM patient-derived stem-like cells (GSCs) (Table S4), which recapitulate 
GBM biology when orthotopically engrafted in mice, and are known to be highly resistant to IR 
(Bao et al., 2006; Dahan et al., 2014). GSC line TS528, which expresses endogenous FGFR2 
and PTEN (Figure 2A), contained a detectable pY240 signal that was eliminated by omitting 
FGF from the culture medium or by treatment with the FGFR inhibitor PD173074 (Figure 2B).  
This in turn resulted in significantly greater IR sensitivity as shown by a sustained pH2AX signal 
(Figure 2C) and fewer colonies formed in an extreme limiting dilution assay (ELDA) after IR 
exposure. In sharp contrast, non-irradiated cells in all conditions formed the same number of 
colonies (Figure 2D), indicating FGFR signaling is critical in facilitating DNA repair. To 
determine whether these effects mediated by FGFR signaling were through PTEN Y240 
phosphorylation, GSC line HK281, which expresses endogenous FGFR2 but is PTEN deficient 
 (Figure 2A), was reconstituted with WT- or Y240F-PTEN followed by assessment of DSB repair 
after IR treatment (Figure 2E). WT-PTEN reconstituted cells showed decreased levels of pH2AX 
(Figure 2F) and increased colony forming efficiency after treatment with IR compared to Y240F-
PTEN cells, while control cells showed no difference in survival (Figure 2G). These results 
suggest that FGFR2 mediated phosphorylation of Y240 PTEN is critical for cells to survive IR 
induced DNA damage. Of note, both WT- and Y240F-PTEN reconstituted cells showed 
increased IR resistance compared to cells without PTEN expression, indicating that in addition 
to phosphorylation of Y240, other properties of PTEN might be involved in the DNA repair 
process, such as other types of protein modifications (Bassi et al., 2013). 
Nuclear localization and chromatin association of pY240-PTEN is elevated in response to 
IR treatment 
   We next investigated the subcellular localization of pY240-PTEN. As shown in Figure 3A, 
although there was a greater total amount of PTEN in the cytosol, the proportion of the pY240-
PTEN was greater in the nucleus, indicating that the majority of nuclear PTEN was 
phosphorylated at tyrosine 240. In agreement with this, we detected a greater level of nuclear 
localized WT-PTEN than Y240F-PTEN in U87 cells especially after IR treatment, while total 
PTEN level and other subcellular distribution remained the same (Figure 3B, S2A). In addition, 
when preparing chromatin-bound protein fractions, we found that WT-PTEN could bind to 
chromatin and this binding was enhanced upon IR treatment (Figure 3C). Interestingly, this 
marked increase in WT-PTEN binding paralleled an increase of pY240 signal, which could be 
induced by IR as early as 1 hr after treatment (Figure 3D-E), suggesting pY240 was involved in 
a relatively early cellular response to IR. In contrast, Y240F-PTEN was clearly compromised for 
association with chromatin (Figure 3C-D), indicating that phosphorylation of Y240 was critical in 
this process. While no further activation of FGFR2 was found after IR treatment as indicated by 
phosphorylation of the receptor at Try653/654 and downstream effector phosphor-ERK (Figure 
S2B), we found an increase in nuclear localization of FGFR2 in parallel with the rapid increase 
of pY240-PTEN after IR treatment (Figure S2C and Figure 3E). Moreover, loading of RAD51 
onto chromatin after IR treatment was noticeably enhanced in WT-PTEN cells (Figure 3C-D). 
The difference of Rad51 loading between WT- and Y240F-PTEN cells was not associated with 
cell cycle distribution, as no significant difference was found in cell cycle profiles up to 8 hr after 
IR. However, in agreement with our data, this treatment did induce cell cycle arrest 24 hr after 
IR in Y240F-PTEN and vector control cells (Figure S2D), indicating the cells are less efficient in 
repairing damaged DNA.  
    In conjunction with these findings, WT-PTEN cells showed decreased chromatin-associated 
trimethylation of lysine 9 of histone 3 (H3K9m3), a marker for condensed chromatin, around 6 hr 
after IR (Figure 3F), suggesting that PTEN binding might promote relaxation of chromatin, which 
is known to facilitate entry of the DNA repair complex to sites of damage (Price and D'Andrea, 
2013; Soria et al., 2012; Wang et al., 2013).  In agreement with this, micrococcal nuclease 
treatment of chromatin revealed greater DNA accessibility in WT-PTEN cells than in Y240F-
PTEN cells after IR treatment, as indicated by nucleosome laddering (Figure S2E). Further 
investigation is needed to reveal how pY240-PTEN regulates chromatin state. Blocking PTEN 
phosphorylation with the FGFR inhibitor PD173074 led to decrease in PTEN and RAD51 
chromatin binding after IR along with a corresponding increase in pH2AX signal (Figure 3G). 
SUMOylation modification, shown to regulate PTEN nuclear localization and DNA damage 
response (DDR) (Bassi et al., 2013), was found to be similar between WT- and Y240F-PTEN 
cells (Figure S2F) and SUMOylation-deficient PTEN (K245R mutation) still can be 
phosphorylated at Y240 (Figure S2G). Thus, SUMOylation and Y240 phosphorylation are 
independent of each other and may regulate PTEN function separately.   
Regulation of DNA damage response by phosphorylation of PTEN tyrosine 240 is 
independent of its lipid phosphatase activity  
We next investigated whether the role of pY240-PTEN in DNA repair is dependent on its 
phosphatase activity. We introduced the G129R-PTEN mutant, known to be defective for 
phosphatase activity (Furnari et al., 1997; Myers et al., 1997), into U87 cells and found it to be 
competent for Y240 phosphorylation (Figure 4A), and behaved similarly to WT-PTEN in its 
ability to mediate DSB repair, as illustrated by pH2AX immunoblotting (Figure 4B), JH2AX and 
RAD51 foci formation dynamics (Figure 4C-D), and colony formation assay after treatment with 
IR (Figure 4E). Another phosphatase defective PTEN mutant, C124S, was also examined and 
similarly, this mutant was competent for Y240 phosphorylation and displayed DNA damage 
repair function identical to WT-PTEN (Figure S3A-B). These results indicate PTEN phosphatase 
activity was dispensable for the DNA repair process. Of note, however, colonies from G129R 
PTEN cells were approximately two-fold larger than those from WT- or Y240F-PTEN cells 
(Figure S3C-D). We suggest that this difference in colony size might result from permissive, 
growth-promoting AKT signaling in G129R-PTEN cells that is absent from WT- and Y240F-
PTEN cells (Figure 4F). These results point to a separation in PTEN functions between its 
canonical role in blocking PI3K/AKT pathway activation, which is dependent on its lipid 
phosphatase activity in the cytosol, and a non-canonical role in regulating DSB repair in a 
 phosphatase independent manner in the nucleus. Thus, our findings demonstrate that effective 
therapeutic strategies for GBM patients might be tailored based on PTEN mutation and Y240 
phosphorylation status (Figure 4G). To further demonstrate the PTEN phosphatase-
independent activity in DSB repair, we generated Y240 phosphorylation-resistant, phosphatase 
activity defective Y240F-G129R double mutant PTEN, and found cells expressing this construct 
were sensitive to IR (Figure 4H). In agreement with the above results, PTEN phosphatase 
activity was not required for chromatin association (Figure 3F, 4I), however, the Y240F-G129R 
double mutant negated the chromatin binding of G129R-PTEN (Figure 4I), indicating the critical 
role of this phosphorylation site in DNA repair. In our assays, we noticed that G129R-PTEN 
bound to chromatin more efficiently than WT-PTEN in all conditions, which might be due to a 
higher pY240 level in G129R-PTEN (Figure S3E). 
pY240-PTEN binds to chromatin through interaction with Ki-67 
Since PTEN lacks a DNA binding domain, we postulated that its association with chromatin is 
mediated by other factors. To determine which protein(s) recruit pY240-PTEN to chromatin, we 
performed mass spectrometric analysis for PTEN binding proteins (Figure 5A). Of the possible 
PTEN binding partners found, the most robustly enriched protein was Ki-67 (Figure 5B), which 
was confirmed by co-immunoprecipitation of endogenous Ki-67 with Flag-tagged PTEN (Figure 
5C). Ki-67 is a well-known marker of cell proliferation but its exact function remains unclear. 
Moreover, although Ki-67 levels were similar in cell expressing WT-, Y240F- or G129R-PTEN, 
the level of chromatin-bound Y240F-PTEN observed was greatly reduced (Figure 5D), in 
agreement with disrupted interaction with Ki-67 (Figure 5E), indicating pY240-PTEN is critical 
for the association of PTEN with Ki-67. Furthermore, knockdown of Ki-67 deceased the level of 
chromatin bound PTEN without affecting total PTEN levels (Figure 5F).  
Ki-67 contains a Forkhead-associated (FHA) domain, a protein phosphatase 1 (PP1)-binding 
domain (PP1-%'WDQGHPUHSHDWVRIDFRQVHUYHG³Ki-67 PRWLI´DQGD&-terminal LR domain. 
Through co-immunoprecipitation experiments using Ki-67 truncations, we found the PP1-BD of 
Ki-67 was essential for the interaction of Ki-67 with PTEN (Figure 5G). Ki-67 has been 
previously shown to be a PP1Jinteracting protein (Booth et al., 2014) through RVxF, )) and 
KiR-SLiM binding pockets present at its phosphatase domain. Although the sequence identity 
between PP1J and PTEN is not very high, according to different structural alignment methods, 
they share significant 3D structure similarity in a hydrophobic pocket located near their 
phosphatase domains, which PP1J uses to bind to the Ki-67 KiR-SLiM motif (Figure S4A-D). 
 Thus, we performed in silico binding studies using sub-microsecond Molecular Dynamics (MD) 
simulations (Table S5). We observed that phosphorylation of PTEN at Y240 favored significant 
closing of the cleft between its PD and C2 domains and increased the accessibility of the PD 
binding pocket (Figure S4E-F). In blind simulations, Ki-67 spontaneously docked to the 
hydrophobic pocket of PTEN homologous with PPIJ (Figure 5H and Movie S1), forming a stable 
complex. The anchoring of Ki-67 to pY240-PTEN was mainly mediated by the KiR-SLiM motif 
(Figure 5I) and stable complexes were also formed when this motif was placed near its binding 
pocket of PTEN in the crystallographic orientation (Figure S4G-H). In addition, while a disrupted 
Ki-67 PP1-BD ablated interaction with PTEN, this domain alone was sufficient for interaction but 
with compromised affinity (Figure S4I). This might be related to the distinct subcellular 
distribution of this small protein, as it displayed a diffuse pattern due to lack of chromatin binding 
domain (LR), while other truncations had a punctate pattern (Figure S4I, right). In agreement 
with this, PTEN chromatin loading was rescued by construct 6 but not 7 in Ki-67 knock down 
cells (Figure S4J). The importance of the PP1-BD for PTEN interaction was further 
demonstrated by transfection of a Ki-67 peptide containing the KiR-SLiM motif, which disrupted 
the interaction (Figure S4K-L) and led to less efficient DNA repair, as indicated by persistent 
DNA damage at 4 hr after IR treatment (Figure S4M), when compared to a mutant peptide 
control. Furthermore, PP1J was able to compete with PTEN for interaction with Ki-67 leading to 
a decrease in PTEN chromatin loading (Figure S4N). Together, these data suggest that pY240-
PTEN is recruited to chromatin through interaction with the PP1-BD of Ki-67. 
Y240F-Pten knock-in mice are more sensitive to IR treatment 
To determine the effect of blocking PTEN Y240 phosphorylation within the context of an 
entire organism, we generated Y240F-Pten knock-in mice (Figures S5A-C). These Y240F mice 
developed normally and were indistinguishable from their wild type littermates. Embryonic 
fibroblasts (MEFs) isolated from these mice showed that the Y240F mutation did not affect 
primary pathways related to cell survival and proliferation, such as EGFR/ERK and AKT 
signaling (Figure S5D).   
In adults, neural stem cells (NSCs) are predominantly found in the subgranular zone of the 
dentate gyrus of the hippocampus (SGZ) and the subventricular zone (SVZ) (Revishchin et al., 
2008), both of which are a source for glioma cell of origin as well as a cell reservoir to 
repopulate the brain after radiation treatment (Chen et al., 2015). We isolated NSCs from the 
SGV from E16.5 WT- and Y240F-Pten knock-in mice. While neurospheres from Y240F-Pten 
 knock-in mice possessed identical AKT activation as WT-Pten neurospheres (Figure S5E), WT-
Pten cells were found to be more resistant to IR than Y240F-Pten cells (Figures 6A-C), 
indicating that preventing PTEN Y240 phosphorylation in an isogenic system with endogenous 
levels of PTEN expression confers sensitivity to DNA damage. More importantly, to test the 
systemic protective effect of PTEN Y240 phosphorylation against IR induced DNA damage in an 
immune proficient background, we treated Pten knock-in mice with whole body IR followed by 
examination of damaged intestinal crypts, which have been shown to express FGFRs and be 
highly sensitive to IR due to their rapid turnover rate (Brodrick et al., 2011; Matsuda et al., 
2012). We found a similar extent of crypt loss at 24 hr after treatment for both mice, however, 
while Pten WT mice completely recovered crypt morphology after 4 day, Y240F-Pten mice still 
had significant crypt destruction and shortened villus length at this time point (Figure 6D) and Ki-
67 staining for proliferating cells within crypts (Figure 6E), which co-registered with pY240-
PTEN positivity (Figure 6E, right). In addition, we generated a glioma model, in which we 
transduced astrocytes from Y240F knock-in mice with the EGFRvIII oncogene to generate 
tumorigenic cell lines (Figure 6F). Upon orthotopic engraftment the mice were irradiated, 
compared with mice harboring EGFRvIII/WT-Pten astrocytes, mice engrafted with 
EGFRvIII/Y240F-Pten astrocytes had extended overall survival, and a decreased tumor burden 
(Figure 6G-H).  These results confirm that pY240-PTEN mediates radioresistance and suggest 
an actionable mechanism that can be targeted for therapy. 
Inhibiting PTEN Y240 phosphorylation sensitizes to therapies  
Motivated by the above results, we sought to develop a preclinical model to determine if 
inhibiting PTEN Y240 phosphorylation would sensitize tumors to IR. Mice orthotopically 
engrafted with TS528 glioma neurospheres expressing endogenous PTEN and FGFR2 (Figure 
2A) were orally administered with the FGFR inhibitor AZD4547, which penetrates the blood 
brain barrier (BBB), and tumors were taken over the course of eight hours to determine a 
therapeutic window at which maximum inhibition of PTEN Y240 phosphorylation was achieved.  
As shown in Figure 7A, phosphorylation of Y240 was reduced to the lowest level at 4 hr and 
returned to the untreated level at 8 hr post-treatment. Based on this pharmacodynamic 
behavior, we designed an experiment to assess tumor growth and animal survival (Figure 7B). 
Mice with engrafted tumors treated with IR 4 hr after AZD4547 administration (when pY240 was 
at the lowest level) had significant tumor growth inhibition (Figures 7C-E) and a corresponding 
increase in survival (Figure 7F). We tested two additional GBM patient-derived GSCs, GSC2 
 and GS 10-6, which yielded similar responses both in vitro (Figures S6A-C) and in vivo (Figure 
S6D-E) to IR after FGFR inhibition. 
To determine if this combination treatment caused systematic toxicity, we examined both 
nude mice and Y240-Pten knock in mice and found the treatment was well tolerated as no 
damage of major organs (Figure S6F and S6G) or body weight loss (Figure S6H) were 
detected.  We also examined brains from tumor-bearing mice after treatment for cell death and 
detected an increased TUNEL signal in tumor tissue but not in surrounding normal brain, thus 
further confirming our treatment regimen had no adverse effect on normal tissues (Figure S6I). 
These results suggest that pharmacological blockade of PTEN Y240 phosphorylation, by FGFR 
inhibitor, could serve as an adjuvant approach for radiotherapy.  
To expand upon the clinical significance of pY240-PTEN, we examined the effect of two DNA 
damage inducing agents, doxorubicin and temozolomide (TMZ), that have been widely used for 
cancer treatment.  Both agents induced greater DNA damage in Y240F-PTEN cells compared 
to WT-PTEN cells (Figure S7A). Furthermore, it has been shown that EGFR inhibitors, such as 
erlotinib, can cause DNA damage (Li et al., 2008) and indeed we found an increase in pH2AX in 
an EGFRvIII-expressing neurosphere line treated with erlotinib (Figure S7B) and detected less 
DNA damage in WT-PTEN cells compared with Y240F-PTEN cells (Figure S7C). These results 
indicate a broad function of pY240-PTEN in protecting cells from different DNA damage stimuli. 
Finally, in an assay that mimics heterogeneous tumor growth, a hallmark of GBM, HK281 
cells expressing RFP720-WT-, BFP-Y240F-, GFP-G129R-PTEN, or GFP-G129R/Y240F-PTEN 
were mixed in equal amounts. IR treatment reduced the percentage of Y240F-PTEN cells in the 
mixed population as well as the double mutant G129R/Y240F cells, while both WT- and G129R-
PTEN cells displayed a survival advantage (Figure S7D). In these cultures, approximating a 
tumor heterogeneous scenario and in agreement with our previous clinical findings that WT-
PTEN expression confers resistance to radiotherapy. 
DISCUSSION 
Our data demonstrate a critical role of PTEN, when phosphorylated at tyrosine 240, in 
mediating resistance to radiotherapy and suggest that inhibiting this phosphorylation event, 
through FGFR inhibition, may be an important adjuvant therapy to increase radiosensitization in 
cancers utilizing this signaling pathway, such as in gastric cancer and GBM. 
 Nuclear PTEN has been linked to chromatin condensation or heterochromatin structure 
(Chen et al., 2014). However, we found chromatin decondensation after IR in WT and G129R-
PTEN cells but not in Y240F-PTEN cells. Of note, while chromatin relaxation happens starting 4 
hr after IR, phosphorylation of PTEN Y240 and its chromatin association was induced as early 
as 1 hr after IR treatment. The delayed chromatin status change after PTEN association may 
indicate PTEN-mediated regulation of chromatin condensation is indirect, the underlying 
mechanism, potentially involving regulation of lysine demethylases targeting H3K9me3 or 
alterations in chromosome condensation proteins, such as associated with condesin I and II 
complexes (Floyd et al., 2013), needs to be investigated further.  
Our data demonstrated that Ki-67 recruits PTEN in a Y240 phosphorylation-dependent 
manner through its PP1-BD, previously shown to bind to PP1J We also observed competition 
between PTEN and PP1J for Ki-67 association, suggesting a mechanism that regulates affinity 
of Ki-67 binding partners. Using a Ki-67 peptide containing the KiR-SLiM motif of the PP1-BD, 
we were able to reduce PTEN and Ki-67 interaction and promote persistent DNA damage after 
IR treatment. Although such an approach proved to be an effective way to disrupt PTEN-Ki-67 
interaction, its utility is likely limited as it may also affect the binding of PP1J to Ki-67. To this 
point, recent studies have shown that Ki-67 may be involved in regulating chromatin structure 
and promoting dispersal of mitotic chromosomes (Cuylen et al., 2016; Sobecki et al., 2016). Our 
data perhaps suggest an interpaly between pY240-PTEN and PP1J, through their interactions 
with Ki-67, contribute to chromatin structure modulation.  
     PTEN phosphatase activity was not required for regulating DNA repair as indicated in our 
study. G129R-PTEN, a phosphatase inactive mutant, showed even stronger chromatin loading 
than WT-PTEN but did not show greater DNA repair ability, which possibly indicate that the 
DDR function of chromatin-associated PTEN has plateaued in these cells under our 
experimental conditions. While G129R-PTEN behaved similar to WT-PTEN in protecting cells 
from DNA damage, it lost the ability to control cell proliferation mediated by the AKT pathway. 
Thus, tumors harboring PTEN mutant G129R, or similar phosphatase deficient mutants such as 
C124S, may represent a clinical situation that is worse than PTEN deficiency, as the 
phosphatase inactivating mutation lacks cell proliferation control but retains the ability to 
enhance DDR through the nuclear function defined here. These data point the way to future 
development of therapeutic strategies to improve clinical outcomes based on PTEN mutation 
and pY240 status. Specifically, patients whose tumors are PTEN deficient might benefit from 
PI3K/AKT inhibition in combination with IR; tumors with WT-PTEN could be treated with FGFR 
 inhibitors plus IR; while tumors with a catalytically inactive PTEN mutation would be best 
targeted with FGFR and AKT pathway inhibitors and IR treatment. Given that tumors can be 
heterogeneous for PTEN mutation and Y240 phosphorylation, we would also anticipate regional 
tumor responses to radiotherapy, which we have mimicked experimentally with mixed cultures 
of WT- and Y240F-PTEN neurospheres.   
     FGFR pathway signaling has been shown to be associated with developmental defects, 
angiogenesis and wound repair abnormalities, cancers, and metabolic disorders. For this study, 
we focused on FGFR2 although other FGFR family members demonstrate specificity for PTEN 
Y240 in a tyrosine kinase screen (data not shown), which raises the possibility that tumors 
derived from different tissues might utilize alternative tyrosine kinases to phosphorylate Y240, a 
prospect that we are currently investigating. The FGFR-TACC fusion protein caused by 
chromosomal translocation has constitutive kinase activity and induces mitotic and 
chromosomal segregation defects and triggers aneuploidy, was recently reported to exist in a 
subset of GBMs (Singh et al., 2012). Whether this fusion protein also phosphorylates PTEN 
Y240 to promote DDR, is yet to be determined.  
Nuclear translocation of tyrosine kinases, such as c-Abl and EGFR, have been found to be 
increased by DNA damage agents (Dittmann et al., 2010; Yoshida and Miki, 2005). Numerous 
studies have reported that FGFRs can translocate to the nucleus and are associated with 
cancer development. In our study, we found IR treatment slightly enhanced FGFR2 nuclear 
translocation and simultaneously, phosphorylation of Y240 PTEN. We thus speculate that under 
DNA damage conditions, tumor cells have an inherent ability to survive through activation of this 
nuclear PTEN function mediated partly by increased FGFR2 nuclear translocation. Together 
with other studies, our data provide a rationale for clinical development of FGFR inhibitors for 
treating GBM resistant to therapies that rely on DNA damage generation. We identify pY240-
PTEN as a predictor for FGFR inhibitor application and thus illustrates an approach for precision 
medicine.  
In summary, our data shows that pY240-PTEN mediates resistance to DNA damage through 
enhancement of the DNA repair process. This particular phosphorylation-related function of 
PTEN is separate from its canonical function of opposing AKT pathway activation. 
Pharmacological blocking of Y240 phosphorylation by FGFR inhibitors sensitized cells to DNA 
damage and extended survival in a preclinical GBM model treated with IR. Therefore, 
understanding the genetic status of PTEN in tumors, such as deletion, wild type, enzyme-
 inactivating mutation, or posttranslational modifications, may help to determine more effective 
treatments for GBM patients. The mechanisms documented here likely also have implications 
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 FIGURE LEGENDS 
Figure 1. FGFR2-mediated phosphorylation of PTEN tyrosine 240 protects cells from DNA damage 
by facilitating DNA repair 
 (A) Tumor samples from 19 GBM patients were stained with pY240-PTEN and pH2AX antibodies. 
Representative images for different staining intensity and quantification of the staining results are shown 
(Fisher's exact test) between pY240-PTEN and pH2AX. Scale bar, 100 µm. (B) In vitro kinase assay was 
performed by incubating recombinant FGFR2 and Src with recombinant GST-PTEN (WT and Y240F 
(YF)). A phos-tag gel was used to separate the phosphorylated and un-phosphorylated protein followed 
by probing with anti-pY240-PTEN antibody and a pan-tyrosine phosphorylation antibody, 4G10. (C) 293T 
cells were transfected with FGFR2 [1. Y486F; 2. Y586F; 3. Y733F; 4. Y769F; 5. Y586/588F; 6. 
Y656/657F (kinase dead); 7. WT] together with Flag-tagged PTEN. Cell lysates were prepared for 
immunoprecipitation followed by immunoblotting with anti-pY240-PTEN. (D) 43 patient-derived glioma 
stem cell lines were evaluated for PTEN and FGFRs expression by RNAseq and for radiation sensitivity 
by clonogenic assay. Distribution of radiation sensitive and radiation resistant samples in PTEN high 
versus PTEN low group are shown. Orange rectangle indicates all radiation sensitive samples in PTEN 
low group showed low level of FGFR2 expression. PTEN high/PTEN low, PTEN expression is 
higher/lower than the median value (RNAseq); FGFR2 low, FGFR2 expression is lower than median 
value (RNAseq) (E) U87-WT/YF-PTEN cells in the presence of FGFR2 were treated with or without IR (0-
10 Gy) and seeded in 10 cm dishes. Colonies were counted after 14 days and surviving fraction was 
calculated as the ratio of the plating efficiency of the treated cells to that of control cells. Data represents 
mean ± SEM from six independent experiments, *p<0.05. (F) U87-empty vector (V), WT/YF- PTEN cells, 
together with FGFR2 were irradiated with 10 Gy and then subjected to the comet assay at indicated time 
points. Tail moment was quantified and graphed for each group. Scale bar, 500 µm. (G) U87-WT/YF-
PTEN cells were irradiated with 10 Gy and DNA damage response pathway was examined by western 
blot at indicated times. Numbers at bottom showed a ratio of pH2AX levels relative to time 0 after 
normalization to actin, *p<0.05 was generated by comparing WT- and YF-PTEN samples at the same 
times. (H and I) Cells were treated with 10 Gy IR and then were stained at the indicated times with 
antibodies to JH2AX (H) and RAD51 (I). Cells containing more than 8 foci (JH2AX) or 5 foci (RAD51) were 
scored as positive. Scale bar, 25 µm. (F, H and I) Error bars are SD of at least three replicates and 
represent at least three independent experiments., *p<0.05. (J) Schematic representative of DNA damage 
pathway and pY240-PTEN is involved in regulating RAD51 recruitment to damaged DNA. See also Table 
S1-3 and Figure S1. 
 
Figure 2. pY240-PTEN confers resistance to DNA damage in GBM stem-like cells  
(A) 10 GBM stem cell lines were examined for PTEN and FGFR2 protein expression. (B) TS528 cells 
were treated with or without 1 µM FGFR inhibitor (PD173074, +PD) or grown in absence of bFGF (-FGF) 
 for 16 hr. Immunoprecipitation of PTEN was performed followed by immunoblotting to examine for pY240 
PTEN. (C) TS528 cells from (B) were treated with or without 5 Gy IR and analyzed for pH2AX by western 
blot.  (D) Cells from (B) were analyzed for survival by limiting dilution assay. (E) HK281 cells reconstituted 
with empty vector (V), WT- or YF- PTEN were examined for pY240-PTEN by immunoprecipitation-
western blot. (F and G) HK281 cells treated with 5 Gy IR were examined for pH2AX (F) and survival (G). 
Data are reported as mean ± SD from three independent experiments. **p<0.01. See also Table S4. 
Figure 3. Nuclear localization and chromatin association of pY240 PTEN was elevated in response 
to IR treatment  
(A) 293T cells were co-transfected with FGFR2 or empty vector along with WT- or YF-PTEN. Cytoplasm 
(C) and nuclear fractions (N) were prepared for detection of pY240-PTEN. Bar graph on the right 
represents the ratio of cytoplasmic or nuclear pY240-PTEN to total cytoplasmic or nuclear PTEN 
respectively (bands inside the boxes). left panel represents the expression level of the indicated proteins 
in whole cell lysates. (B) U87-WT/YF-PTEN cells along with FGFR2 were irradiated at 10 Gy and whole 
cell lysates (left top) and cell fractionations (left bottom and right) were collected at indicated times 
followed by immunoblotting with anti-PTEN and anti-FGFR2 antibodies. Results represent equal cell 
equivalents of nuclear and cytosolic fractions. WCL, whole cell lysates; C, cytoplasm; N, nuclear. Long 
expo, longer exposure time. (C) U87-WT/YF-PTEN cells were treated with 10 Gy IR and chromatin 
fractions were prepared at the indicated times. PTEN and RAD51 from chromatin fraction (Chr) and WCL 
were examined by western blot. NCL, nucleolin, used as loading control for chromatin fraction. (D) 
Chromatin bound total PTEN and pY240 PTEN from WT or YF PTEN overexpressing 293T cells was 
compared by western blot over time after treatment with 10 Gy IR. (E) pY240-PTEN was monitored over 
time up to 24 hr after IR treatment in 293T cells. (F) Chromatin bound total PTEN, RAD51 and 
trimethylation lysine 9 of histone 3 (H3K9m3) were compared by western blot over time after treatment of 
WT-, YF- or GR-PTEN reconstituted cells with 10 Gy IR. Numbers in C, D, F indicate ratio of RAD51 
levels relative to time 0 after normalization to NCL, *p<0.05 was generated by comparing WT- and YF-
PTEN samples at the same time point. (G) Chromatin bound PTEN was assessed in U87-WT PTEN with 
and without 1 µM PD173074 treatment and normalized to NCL (bar graph). Error bars in this figure 
represent SD of three independent experiments, *p<0.05. See also Figure S2 
Figure 4. Regulation of DNA damage response by phosphorylation of PTEN tyrosine 240 is 
independent of its lipid phosphatase activity 
(A) U87-WT/YF/GR-PTEN cells were examined for pY240 by western blot. (B) Cells from (A) were 
treated with 10 Gy IR and analyzed for pH2AX at indicated times. (C and D) Cells from (A) were treated 
with 10 Gy IR and analyzed by immunofluorescence at the indicated times for the presence DSBs. 
Quantification of Ȗ+$;(C) and RAD51 (D) foci positive cells is shown. (E) Cells treated as (C) were 
analyzed for colony formation. (F) U87-WT/YF/GR-PTEN cells were examined for AKT phosphorylation at 
Ser473 by western blot. (G) Proposed therapeutic strategies for GBM patients according to PTEN genetic 
status and phosphorylation of Y240. (H) HK281 cells reconstituted with WT-, YF-, or GR/YF-PTEN were 
 treated with or without 3 Gy IR and analyzed for survival by limiting dilution assay. (I) U87-WT/YF/GR- or 
G129R/Y240F (GR/YF)-PTEN cells along with FGFR2 were treated with 10 Gy IR and chromatin-bound 
protein isolated at indicated times post-IR was immunoblotted for PTEN and RAD51.  Error bars in this 
figure are SD of three independent experiments. *p<0.05. See also Figure S3. 
Figure 5. pY240-PTEN binds to chromatin through interaction with Ki-67  
(A) Schematic for the identification of PTEN binding proteins. U87 cells expressing empty vector or Flag-
GR-PTEN were labeled in SILAC media containing either light or heavy lysine and arginine. Chromatin 
fractionation followed by anti-Flag immunoprecipitation (IP) was performed for each sample, and 
immunoprecipitated proteins were combined and analyzed by mass spectrometry (MS).  (B) Scatter plot 
of the median ratio of PTEN/mock for every protein identified with at least 3 unique peptides from two 
biological samples were plotted on a log3 scale. Each data point represents a single protein that was 
identified in this experiment. Data represent two biological repeats by labeling cells with different isotope 
(heavy or light). (C) Immunoprecipitation of Ki-67 or Flag (PTEN) from chromatin fractions of U87-V or 
GR-PTEN cells followed by blotting with Ki-67- or PTEN- specific antibody. (D) Chromatin bound Ki-67 in 
U87-WT/YF/GR-PTEN cells was determined by western blot. (E) Chromatin fractions from indicated cells 
were prepared for immunoprecipitation with anti-Ki-67 antibody followed by western blotting with PTEN 
antibody. (F) U87-GR-PTEN cells were transfected with two siRNAs targeting Ki-67 (si-1 and si-2) and a 
non-specific control (NC). Chromatin fractions were isolated to examine Ki-67 and PTEN levels by 
western blot. (G) 293T cells were co-transfected with PTEN and Ki-67 truncations (mNeoGreen-tagged). 
Whole cell lysates were prepared for co-IP with mNeoGreen (mG) antibody followed by western blotting 
with PTEN antibody; lane 1, Full length Ki-67; lane 2, LR domain lacking (deletion of 2929±3256 aa); lane 
3, FHA domain lacking (deletion of 1±134 aa); lane 4, FHA and PP1-BD (deletion of 1±1002 aa); FHA, 
lane 5, PP1-BD and 8 repeats (deletion of 1-1970 aa). #6, 16 repeats deletion; #7, disrupted FHA and 
PP1-BD from #6; #8, PP1-BD only. (H) Left: snapshots of Ki-67 trajectory color-coded by the simulation, 
ZLWKWKHDOLJQHGELQGLQJSRFNHWVRI37(1EOXHDQG33ȖUHGKLJKOLJKWHGLQDVTXDUH&HQWHU]RRPLQ
at the alignment of the structurally conserved region containing the RVxF and KiR-SLiM binding pockets 
in pY240-37(1EOXHDQG33ȖUHG5LJKWFRPSDULVRQEHWZHHQWKHKi-67/pY240-PTEN complex 
formed in simulation (above) and the Ki-67/33ȖFU\VWDOORJUDSKLFFRPSOH[EHORZ(I) Close-up to the Ki-
67 interaction (orange) with pY240-PTEN, showing the conserved phosphatase fold in blue. The main 
RVxF motif and KiR-SLiM Ki-67 residues appear in licorice, with the closest interactions labeled. See also 
Figure S4, Table S5 and movie S1. 
Figure 6. Y240F-Pten knock-in mice are more sensitive to IR treatment 
(A) Primary neurospheres were prepared from E16.5 WT and Y240F-Pten mice embryos and cell lysates 
from two representative Y240F Pten neurospheres (YF-1 ad YF-2) and one WT Pten neurosphere were 
prepared, immunoprecipitated with anti-PTEN antibody and examined for pY240-PTEN. (B) 
 Neurospheres were treated with or without 3 Gy IR. Cell lysates were collected at indicated times and 
pH2AX was examined. (C) Survival of neurospheres treated as in (B) were evaluated by limiting dilution 
assay. (D) WT- and YF-Pten mice were treated with 8Gy whole body IR. Representative images show 
H&E staining of sections from proximal small intestine at indicated times post IR. Scale bar, 100 µM. Bar 
graph on the right indicates villus height measured from H&E staining images. (E) Representative images 
of Ki-67 staining indicating proliferating cells in intestinal crypts and pY240-PTEN staining from mice in 
(D). Scale bar, 200 µM. Inset scale bar, 50 µM. Bar graph on the right indicates quantification of Ki-67-
positive cells per crypt. 30 crypts were assessed from each mouse. (F) Astrocytes from Cdkn2a null; WT- 
and YF Pten mice were transduced with EGFRvIII to generate tumorigenic cell lines. Western blot 
illustrates expression of EGFRvIII, with U87 cells stably reconstituted with EGFRvIII as control. (G) Cells 
from panel (F) were used for intra-cranial engraftment (0.5x106 per mouse) followed by IR treatment after 
tumor establishment. Representative images at day 72 were shown.  (H) Kaplan-Meier analysis of 
survival. Quantification data represent mean ± SD from three independent experiments. *p<0.05. See 
also Figure S5. 
Figure 7. Inhibiting PTEN Y240 phosphorylation sensitizes to therapies  
(A) TS528 cells were intracranially injected into immunodeficient mice to establish tumors. Mice were 
administrated FGFR inhibitor AZD4547 (50 mg/Kg) by gavage at day 12 after injection. Tumor tissues 
were collected at indicated times after treatment and lysates were prepared for immunoprecipitation with 
PTEN. Presence of pY240-PTEN was determined by western blot. (B) Schematic representation of 
preclinical study design and experimental workflow. Tumor burden was evaluated by three-dimensional 
(3D) fluorescence molecular tomographic (FMT) imaging system starting at day 12. (C) Representative 
images of tumor FMT signal taken at day 14 are shown. Ctrl, vehicle; AZD, 50 mg/Kg AZD4547; IR, 2.5 
Gy; AZD (2 hr)-IR or AZD (4 hr)-IR, treated with 2.5 Gy IR after 2 or 4 hr of AZD treatment. (D) 
Quantification of FMT signal intensity from (C). Colored horizontal bars indicate mean value of each 
group. ns, not significant between ctrl group and AZD, IR or AZD (2 hr)-IR group. (E) FMT signal 
monitored starting from day 12 (before treatment) to day 19. Signal intensity recorded from each point 
was quantified relative to day 12. Error bars are SD of at least three replicates. (F) Kaplan-Meier analysis 
of mice survival due to treatments in (B). *p<0.05. See also Figure S6 and S7. 
  
 STAR  Methods 
 
Contact for Reagent and Resource Sharing 
 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Frank B. Furnari (ffurnari@ucsd.edu) 
 
Experimental Model and Subject Details 
 
Mice 
All animal experiments were conducted according to protocols approved by University of 
&DOLIRUQLD6DQ'LHJR¶V,QVWLWXWLRQDO$QLPDO&DUHDQG8VH&RPPLWWHH,$&8&  For Pten knock-
in mice: C57BL/6J mice and E2a-cre mice were obtained from Jackson Lab (Bar Harbor). 
FVB.129-Cdkn2atm1Rdp (Cdkn2a-null) mice were from NCI repository (#01XB2). For Brain tumor 
intracranial models, NU/NU Nude mice were obtained from Charles River Laboratories. All mice 
used were female, aged 4-6 weeks and weight >20 g before experiments started. Mice were 
randomly assigned to experimental groups. All mice were kept up to 4 mice per cage and 
maintained in the vivarium room of Cellular and Molecular Medicine West at University of 
California, San Diego. 
Human GBM tissue sections 
Human GBM specimens were obtained according to a protocol approved by the institutional 
review board of the University of São Paulo and written informed consent was obtained from all 
patients for the use of their samples. Patient characteristics are showed in Table S1. 
Cell Lines and primary cultures 
293T (source: female), human glioma cell line U87 cells (source: male) were cultured in DMEM 
(Hyclone) with 10% heat-inactivated FBS (Hyclone8PO3HQLFLOOLQDQGȝJPO
Streptomycin (Gibico/Life Technologies). GBM stem cell lines TS528, TS543, TS576 and TS600 
were kindly provided by Dr. Cameron Brennan, MSKCC; HK281 was from Dr. Harley Kornblum, 
UCLA; GSC11 (source: male) and GSC23 (source: male) were acquired from Dr. Frederick 
Lang, MD Anderson; GBM6 (source: male) and GBM39 (source: male) were obtained from Dr. 
David James, Northwestern University; GBM1600 (source: male) was kindly provided by Dr. 
Paul Mischel, Ludwig Institute. GBM stem cell (Neurosphere) lines were cultured in DMEM/F12 
 medium supplemented with B27 (GIBCO/Life Technologies) and human recombinant EGF (20 
ng/ml), bFGF (20 ng/ml) and 2 mg/mL heparin (StemCell Technologies). Neurospheres were 
dissociated with Accutase (Stemcell Technologies). Primary neural stem cells were isolated 
from the brain of E16.5 littermates of WT and Y240F PTEN mice. Cells were cultured in the 





Wild type PTEN cDNA was subcloned into the pLV-EF1a-MCS-puro lentiviral plasmid (Biosettia) 
and all the mutant PTEN (Y240F, G129R, C124S, K254R) were acquired by site-directed 
mutagenesis PCR using Phusion high fidelity polymerase and DpnI (New England Bio labs). 
FGFR2 cDNA was subcloned from pCMV vector to lentiviral plasmid pBobi (Life Technology) 
and the mutants (Y486F, Y586F, Y733F, Y769F, Y586/588F and Y656/657F) were generated 
from WT FGFR2 by site-directed mutagenesis PCR. Ki-67 expressing constructs 1-7 (Figure 
5G) were kindly provided by Dr. Daniel W. Gerlich; Ki-67 truncation 8 was generated by overlap 
extension PCR from construct 6, and only contains PP1-binding domain 81 aa (485-565) fused 
to mNeonGreen at the C-terminus. Traffic light 1.1 and SFFV (expressing I-SceI and donor 
GFP) lentiviral plasmids were gifts from Dr. Petra Hamerlik.  
Lentivirus Production and Infection 
pLV-puromycin lentivirus expressing PTEN or FGFR2, was generated by co-transfection with 
969JDQGǻSDckaging plasmids in 293T cells using Lipofectamine 2000 (Life Technologies). 
Supernatants were collected at 48 and 72 hr after transfection and virus was concentrated by 
ultra-centrifugation. The virus pellets were resuspended in HBSS and kept in -80 °C until use. 
/HQWLYLUDOWLWHUZDVGHWHUPLQHGXVLQJS(/,6$NLWDFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO
(Clontech). Cells were infected with high titer lentivirus and were subjected to 1 µg/mL 
puromycin selection. 
In vitro kinase assay and Phos-tag gel 
Kinase assays were performed as described (Kang et al., 2007) with the following modifications: 
500 ng of GST-PTEN (WT or Y240F) was used as substrate and reacted with 100ng purified 
recombinant FGFR2 or Src kinase (Millipore) per reaction. Kinase efficiency was analyzed by 
 protein gel where Phos-WDJ$FU\ODPLGH$$/-107 (Wako Pure Chemical Industries) was 
incorporated into the gel to differentiate phosphorylated and un-phosphorylated proteins. 
Electrophoresis and gel transfer were performed according to the manufacturer instructions.  
Western Blotting and immunoprecipitation 
Cultured cells were lysed with RIPA lysis buffer (50mM Tris-HCl, 150mM NaCl, 0.5% Sodium 
deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitor cocktail 
(Bimake.com). Protein concentration of each sample was determined by BCA assay using the 
BCA kit (ThermoFisher 6FLHQWLILFDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV&HOOO\VDWHVZHUH
analyzed by electrophoresis on SDS-PAGE gel. NuPage 4-12% Bis-Tris and 3-8% Tris-Ace mini 
gels (Novex) were used for Ki-67 electrophoresis. PVDF membrane (Millipore) was used for gel 
transfer and the membrane was probed with primary antibodies as indicated, followed by 
secondary antibodies conjugated with HRP. The signal was detected with Super Signal West 
Pico/Femto Chemiluminescent Substrate (Thermo Scientific). 
For immunoprecipitations, cells were lysed with NP40 buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
0.5% NP40, supplemented with protease and phosphatase inhibitor) for 10 min on ice followed 
by sonication at 10% amplitude for 6 seconds (1s on, 1s off). Supernatant was collected after 
centrifuge at 14,000 × g for 15 min at 4 °C. Immunoprecipitations were performed by gentle 
rotation overnight at 4 °C, and then immune complexes were washed three times in cold NP40 
buffer and resuspended in Laemmli sample buffer. For immunoprecipitation from nuclear or 
chromatin extracts, lysates were diluted 5-fold in NP40 buffer.  Immunoprecipitation of 
endogenous SUMO-PTEN was performed as described (Bassi et al., 2013). Briefly, cells were 
lysed in Laemmli sample buffer (without bromophenol blue), followed by sonication and 
centrifugation at 15,000 × g for 15 min at 4 °C. Supernatant was diluted 10-fold with PBS 
containing fresh 20 mM N-ethylmaleimide (NEM) (Sigma), 1% Triton X-100, 1 mM dithiothreitol 
(DTT), and protease and phosphatase inhibitor cocktail. Anti-Flag affinity gel (Sigma) was 
added and rotated at 4 °C overnight. Immune complexes were washed 4 times with PBS 
containing 1% Triton x-100 and resuspended in Laemmli sample buffer. Co-immunoprecipitation 
of Ki-67 (full length and truncations) and PTEN was performed using mNeoGreen (nAb) 
agarose (Allele Biotechnology) according to manufacturer instructions. 
Analysis of patient derived GSC lines  
 The expression levels of FGFR2 and PTEN in in 43 patient-derived glioma stem cell lines 
(Figure1D) were determined by RNAseq where the median expression value of FGFR2 for all 
lines in this RNAseq experiment was 2.5, based on RPKM values from normalized 
transcriptome sequencing. The lines were dichotomized as either high or low expressing based 
on the median value, which is a well-accepted way to define expression level. This 
unsupervised approach was chosen as opposed to a supervised approach, which would have 
selected the FGFR2 expression cutoff point leading to the greatest difference in radiation 
sensitivity and thus bias our conclusions. Similarly, PTEN expression level is defined as high or 
low based on the median value of all GSC lines in this certain experiment. Note 2.5 is only 
applied in Figure 2D where the RNAseq assay was used for analyzing patient derived GSCs 
and this median value differs between experiments.  
Radiation response was determined as below. Briefly, cells were radiated at 0, 2, 4, or 6 Gy and 
seeded at 1 viable cell per well in 96 well plates. Sufficient plates were used so that at the 
endpoint of the experiment a minimum of 10 positive spheres per experiment could be scored. 
Clonogenicity was determined by normalizing the fraction of wells with spheres to the sphere 
forming rate of the unirradiated cells, which represented the plating efficiency. All experiments 
were conducted in triplicate. Cells were dichotomized as either radiotherapy (RT) sensitive vs. 
RT resistance based on a survival fraction after 4 Gy of radiation of <0.3 or >0.3. This value was 
chosen based on examination of the linear quadratic survival functions for each line and a 
significant separation of the lines at this dose and survival fraction. Intermediate means the cells 
behaved similarly to RT as defined above when treated with higher doses of irradiation (such as 
6 Gy in this assay) treatment. We excluded these samples from Figure 1D and only compare 
the most significantly different ones (RT sensitive and RT resistant).  
Clonogenic assay 
Briefly, cells were treated with different doses (0±10 Gy) of irradiation and seeded in 100-mm 
dishes at appropriate densities in triplicate 2 hr after irradiation. Cells were incubated for 14 day 
to allow the formation of colonies and then colonies were fixed with 4% formaldehyde for 20 min 
at room temperature, washed with PBS, stained for 30 min with 0.5% Crystal Violet, washed 
with water several times and then dried. Colony numbers were counted and the surviving 
fraction was calculated as the ratio of the plating efficiency of the treated cells to that of control 
cells.  
Single cell electrophoresis assay (comet assay) 
 Single cell gel electrophoresis (Neutral) was performed according to PDQXIDFWXUHU¶VLQVWUXFWLRQV. 
Briefly, U87 cells expressing empty vector, WT- or YF-PTEN were irradiated at 10 Gy and were 
collected at 0, 1 and 24 hr after IR, followed by washing and resuspension in ice cold PBS. 1-2 x 
104 cells were prepared for each assay using Comet Assay Electrophoresis system (Trevigen). 
The samples were then analyzed by fluorescence confocal microscopy using an Olympus 
FV1000. Tail moment was analyzed using software provided by Trevigen. 
,PPXQRIOXRUHVFHQWVWDLQLQJRIȖ+$;RAD51, RPA, and BrdU foci 
U87 cells expressing PTEN constructs seeded on coverslips to ~70-80% confluency were 
allowed to attach for 12 hr followed by irradiation at 10 Gy using a gamma-irradiator. For BrdU 
assay, cells were incubated with 20 µM Brdu for 36 hr prior by IR treatment. At indicated time 
points, cells weUHZDVKHGZLWKFROG3%6&HOOVZHUHLQFXEDWHGLQFROGȝ/RI([WUDFWLRQ
Buffer 1 (10 mM PIPES, pH 7.0; 100 mM NaCl; 300 mM Sucrose; 3 mM MgCl2; 1 mM EGTA, 
0.5% Triton X-RQLFHIRUPLQZDVKHGZLWK3%6DQGWKHQLQFXEDWHGLQFROGȝ/RI
Extraction Buffer 2 (10 mM Tris-HCl, pH 7.5; 10 mM NaCl; 3 mM MgCl2, 1% Tween 40, 0.5% 
sodium deoxycholate) on ice for 10 min. Cells were then washed in cold PBS and fixed in 4% 
PFA for 20 min on ice followed by permeabilization with 0.5% Triton X-100 for 10 min on ice. 
&RYHUVOLSVZHUHWKHQEORFNHGE\LQFXEDWLRQLQȝ/RI%6$LQ3%6RQLFHIRUPLQ
followed by 5% donor bovine serum (ThermoFisher Scientific) for 20 min.  Blocked coverslips 
ZHUHWKHQSUREHGZLWKDQWLERGLHVGHWHFWLQJȖ+$;0LOOLSRUH53$DQd RAD51 (Santa Cruz 
Technology), and BrdU (BD Bioscience) followed by Alexa Fluor 488±conjugated secondary 
antibody (Life Technology). Coverslips were mounted with Fluoro-Gel II with DAPI (Electron 
0LFURVFRS\6FLHQFHV)OXRUHVFHQWȖ+$;53$%UG8DQGRAD51 foci were captured by 
confocal microscopy. For quantification, cells containing more than 5 foci were determined as 
positive.  
Traffic Light Reporter (TLR) Assay  
TLR assay was conducted as described (Certo et al., 2011) using U2OS cells with PTEN 
deleted by CRISPR/Cas9 editing. Briefly, U2OS PTEN-/- cells were infected with TLR 1.1 lenti-
virus containing a I-SceI restriction site at MOI=1 followed by puromycin selection to generate 
stable cell lines. The reporter cells were then reconstituted with WT- or Y240F-PTEN together 
with FGFR2. I-SceI and a donor GFP was introduced into the above cells to induce DSB. Cells 
were then allowed to grow for another two days and subjected to FACS analysis to determine 
the proportion of GFP and mCherry positive cells. 
 Micrococcal nuclease (MNase) assay 
MNase was performed in WT- or YF-PTEN U87 cells after IR. Briefly, WT- or YF-PTEN U87 
cells were collected after IR (10 Gy) treatment at various time points, washed twice with PBS 
and resuspend in 500 µl buffer A (10 nM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.3 M 
sucrose, proteinase inhibitors). Suspensions were mixed gently and left on for 5 min followed by 
addition of 25 µl 10% NP40 on ice for 10 min. Following centrifugation at 1200rpm for 10 min at 
4 °C, pelleted nuclei were resuspended in 200 µL buffer A with 10 mM CaCl2 and 100 U MNase 
was added at room temperature for 3 min.  Reactions were terminated by adding 50 mM EDTA. 
DNA was purified using Qiagene DNA isolation Kit and separated on 1.2% agarose gel. 
Subcellular Fractionation 
Cells were washed with ice-cold PBS and then incubated on ice for 5 min in buffer A (10 mM 
Tris-Cl, pH 7.5, 3 mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 0.5% NP40 and protease inhibitor 
cocktail). The cells were centrifuged at 2,500 rpm at 4°C for 5 min. Supernatant was collected 
and used as the cytosolic fraction. The pellet was washed once with buffer A without NP40, then 
resuspended in buffer C (20 mM HEPES, pH 8.0, 0.4 M NaCl, 7.5 mM MgCl2, 0.2 mM EDTA, 
0.21 mM EGTA, 1 mM DTT, and protease inhibitor cocktail), vigorously vortexed for 30 min at 4 
°C, and resulting homogenates were centrifuged for 10 min at 13,000 rpm at 4°C. Collected 
supernatants from this fraction were then used as nuclear fractions. Nuclear and cytosolic 
fractions were resolved by SDS-PAGE. For Figure S2A, subcellular fraction was prepared using 
Subcellular Protein Fractionation Kit from Thermo Fisher Scientific and Na/K ATPase, MEK1/2 
or GAPDH, HDAC2 or Lamin A/C and Vimentin served as loading controls for plasma 
membrane, cytoplasma, nuclear and cytoskeleton, respectively. 
Chromatin Fraction preparation 
%ULHIO\F\WRSODVPLFSURWHLQZDVILUVWLVRODWHGE\LQFXEDWLRQRIFHOOVLQEXIIHU$(?P0+(3(6DW
S+(?P0.&O(?P00J&O(?0VXFURVHDQGJO\FHUROVXSSOHPHQWHGZLWK
protease inhibitors and 0.1% Triton X-100, followed by centrifugation at 4 °C. The resulting 
SHOOHWZDVUHVXVSHQGHGLQEXIIHU%(?P0('7$(?P0(*7$VXSSOHPHQWHGZLWKSURWHDVH
DQGSKRVSKDWDVHLQKLELWRUVDQGYRUWH[HGIRU(?PLQDW&IROORZHGE\FHQWULIXJDWLRQ7KH
supernatant was collected as the nuclear-soluble fraction, and the pellets were solubilized in ice 
cold RIPA buffer with 500mM NaCl on ice for 30 min followed by centrifugation at 14,000 rpm at 
4 °C for 10 min.  The resulting chromatin fraction supernatant was stored at -80 °C. For SILAC-
 MS analysis, chromatin fractions were digested with Benzonase (Sigma) overnight at 4 °C in 
Benzonase buffer (2 mM MgCl2, 100 mM NaCl, 50mM HEPES, pH 7.5) and then subjected to 
co-immunoprecipitation using anti-Flag affinity gel (Sigma). 
Immunohistochemistry and H&E staining/TUNEL staining 
Tissue sections were prepared from formalin-fixed paraffin-embedded glioblastoma patient 
tumors or mice intestines and staining were performed as below: 0.01 M citrate buffer, pH 6.0 
was used for antigen retrieval for 3 min at 122°C in a pressure cooker. 3% hydrogen peroxide 
was used for peroxidase activity quenching. Primary antibodies for phospho-H2AX (Millipore) 
and phospho-PTEN Y240 were diluted at 1:250 and 1:50 respectively in 10% normal goat 
serum in TBS- 0.1%Tween. Primary antibodies were incubated overnight at 4°C, followed by 
biotinylated secondary antibodies (Vector) at 1:500 dilution for 1 hr at room temperature. Slides 
were counterstained with hematoxylin. Immunostaining was analyzed and scored independently 
by two observers: 0 as negative, 1 as ~ 25% of positive structures were present, 2 for 26-50%, 
3 for 51-75% and 4 for >76% of positive structures. For mice Ki-67 staining, antigen retrieval 
was done by heating slides at 95°C in citrate buffer for 20 min followed by incubating in 3% 
Hydrogen peroxide for 30 min for peroxidase activity quenching. Slides were then blocked with 
Avidin D for 15 min and Biotin for 15 min. Primary antibodies for Ki-67 (Abcam) was used at 
1:100 dilution in 5% normal goat serum in TBS- 0.1%Tween followed by secondary antibody 
and developed according to the instruction of Vectastain Elite ABC Kit and DAB Substrate Kit. 
H&E and TUNEL staining: Tissues from mice were prepared and fixed in Formalin for 24 hr and 
transferred to 70% ethanol. H&E and TUNEL staining were performed and analyzed at the 
UCSD Tissue Technology Core, a shared resource supported by an NCI Cancer Center 
Support Grant (CCSG Grant P30CA23100). 
Extreme Limiting dilution assay (ELDA) 
Extreme limiting dilution assay was performed as described (Hu and Smyth, 2009). In particular, 
TS528 cells were incubated with 1 µM PD173074 or medium without bFGF for 16 hr before 
irradiation. Different dilutions (0, 10, 25, 50, 100 cells/well) for HK281 and TS528 cells and (0, 
25, 50, 100, 200, 400 cells/well) for primary neurosphere cells with or without IR treatment (5 
Gy) were seeded in 96-well plates. After 14-18 days, the number of spheres formed was 
counted and analyzed using an online software application 
(http://bioinf.wehi.edu.au/software/elda/). 
 SILAC Labeling and mass spectrum 
SILAC labeling was described previously(Ong et al., 2002).U87 cells expressing empty vector 
or Flag- GR-PTEN were grown in SILAC DMEM supplemented with 10% dialyzed fetal bovine 
serum and with either light (12C6-L-arginine and 12C6-L-lysine) or heavy (13C6,15N4-L-arginine 
and 13C6,15N2-L-lysine (Cambridge Isotope Laboratories)) for 10 days. Chromatin fractions from 
both cells were prepared as previously described. Samples were eluted in 6 M Urea with 
100mM carbonate and 1M Hydrochloric acid was used to neutralize the carbonate to pH8. The 
,3SURGXFWVIURP³OLJKW´DQG³KHDY\´ODEHOHGFHOOVZHUHFRPELQHGWRJHWKHUIRUPDVVVSHFWUXP
analysis. The IP products were first reduced with 10 mM DTT and alkylated with 30 mM 
iodoacetamide. 50 mM phosphate pH 8.0 was used to dilute the 6M Urea to 1M, and then 1ug 
of trypsin was used to digest the sample. Peptides generated from the digestion were desalted 
using a 50mg Sep-Pak C18 cartridge, and fractionated using HILIC (Hydrophilic Interaction 
Liquid Chromatography) with a linear gradient from 19%- 32% H2O with 0.01% TFA over 24 min 
on a TSKgel Amide-80 1 mm inner diameter column (TOSOH BioSci). The HILIC fractions were 
analyzed by LC-MS/MS on an LTQ XL-Orbitrap Discovery mass spectrometer (MS) with one full 
scan followed by 10 MS2 dependent scans. A Dionex UltiMate 3000 RSLC nano pump was 
used with a 70 min gradient from 12-33 % acetonitrile with 0.1% formic acid and a flow rate of 
300 nl/min. MS data were searched on Sorcerer2-SEQUEST using the reviewed Swiss-Prot 
human database with the following static and variable modifications for the two IPs. The 
modifications for the SILAC IP were K 8.0142 (variable, heavy lysine), R 10.00827(variable, 
heavy arginine), M 15.994920 (static, oxidation), C 57.021465 (static, carbamidomethyl), and 
STY 79.963311(variable, phosphorylation). The Trans-Proteomic Pipeline V4.3 JETSTREAM 
rev1 was used to analyze the search result. A PeptideProphet of 0.8 was applied and the 
common contaminants were removed; the identified peptides were quantified using XPRESS 
and a minimal ion intensity of 1.0E3 was used to calculate the abundance ratio. At least three 
unique peptides were required for a protein or a protein complex to be identified as an PTEN 
binding protein, and the median abundance ratio for each identified protein was calculated and 
plotted. 
Brain tumor intracranial models and IR treatment  
All animal experiments were conducted according to protocols approved by University of 
&DOLIRUQLD6DQ'LHJR¶V,QVWLWXWLRQDO$QLPDO&DUHDQG8VH&RPPLWWHH,$&8&L5)3-
labelled HK281, GSC2 or TS528 cells were injected intracranially into immunodeficient mice, at 
 coordinates 1 mm anterior and 2 mm lateral of the right hemisphere relative to the bregma, at a 
depth of 4 mm followed by 7-10 days of tumor establishment. Tumor burden was monitored 
using a three-dimensional (3D) fluorescence molecular tomographic imaging (FMT 2500, 
PerkinElmer). HK281 cells were first treated with or without 1 µM FGFR inhibitor PD173074 
(Selleck Chemicals) prior to 5 Gy IR and were then engrafted into immunodeficient mice at 
2.0x105/3 µl PBS per mice. Tumor signal intensity was detected at day 12 for control group and 
day 20 for treatment group. Survival was monitored until all mice died. TS528 cells were 
injected at 2.5 x104/1µl PBS per mouse and GSC2 cells were injected at 5.0x105/3 µl PBS per 
mice. At day 12 (TS528 cells) or day 18 (GSC2 cells), mice were administrated FGFR inhibitor 
AZD4547 (Selleck Chemicals) (50 mg/kg by gavage) or vehicle (DMSO) 2 hr or 4 hr before 2.5 
Gy irradiation. This whole treatment process was repeated for 3 consecutive days (day 12-14). 
FMT signal was monitored starting at day 12 until the end of the experiment and percent of 
surviving mice over time was recorded.  
Generation of Y240F-Pten knock-in mice 
A BAC construct containing the mouse Pten was used as a genomic source to create a 
WDUJHWLQJYHFWRU%ULHIO\D¶KRPRORJ\DUPRIH[RQIROORZHGE\H[RQFRQWDLQLQJW\URVLQH
240 to phenylalanine mutation and a right homology arm containing exons 8 and 9 were 
inserted into targeting vector pKO scrambler V915 (Lexicon Genetics Inc., Woodland, TX) 
flanking a LoxP-pGK-Neo-LoxP selection cassette.  The linearized targeting vector was 
electroporated into 129svEv ES cells and clones were screened by southern blot analysis for 
correct targeting into the Pten locus.  Two correctly targeted ES cell clones were injected into 
blastocysts to generate chimeric mice in C57BL/6J.  Mice with greater than 80% chimerism, as 
determined by agouti coat color, were bred with C57BL/6 mice and progeny were screened by 
southern blot to ascertain germline transmission.  Heterozygous mice were bred with E2a-cre 
mice (Jackson Lab, #003314) to excise the pGK-Neo selection cassette and progeny were 
screened by PCR to confirm successful cre-mediated excision.  Heterozygous mice lacking 
pGK-Neo were bred with FVB.129-Cdkn2atm1Rdp (Cdkn2a-null) mice (NCI repository, #01XB2) 
to generate Y240F-Pten KI/KI; Cdkn2a-/- mice.   
Preparation of primary neurospheres from wild type or Y240F Pten knock-in mice 
The isolation of neural stem cell cultures (neurospheres) were conducted using an established 
protocol (Ahlenius and Kokaia, 2010) with some modifications. E16.5 embryos from wild type 
and Y240F Pten knock-in mouse were collected in Ca2+-Mg2+-IUHH+DQNV¶EDODQFHGVDOWVROXWLRQ
 (Sigma). Tissue pieces were dissected from the subventricular zone (SVZ) of the brain and 
were dissociated by incubation with 0.15% trypsin/EDTA (Gibco). Dissociated cells were 
resuspended and maintained in stem cell culture medium. Visible neurospheres formed in 
approximately 4 days and were allowed to expand for an additional 7 days before being used in 
experiments. 
In silico modeling and binding of pY240-PTEN to Ki-67  
The computational studies of pY240-PTEN were based on the reference PDB entry 1D5R(Lee 
et al., 1999), which contains the phosphatase domain (PD) and the C2 domain, with a large 
missing loop (residues 281 to 313). In recent structures of PTEN, a larger fragment of this 
missing region is present (PDB entry: 5BZX), which allowed us to perform a partial 
reconstruction of PTEN286-309 with the modeller suite. The Ki-67 phosphatase-binding fragment 
was obtained from the PDB entry 5J28, which reports the complex formed between Ki-67496-536 
DQGWKHSKRVSKDWDVH33Ȗ)RU0ROHFXODU'\QDPLFV0'6LPXODWLRQVWKHSURWHLQVZHUH
titrated, neutralized, hydrated, minimized, heated and equilibrated using standard protocols. The 
phosphorylation at tyrosine 240 was prepared with the Vienna-PTM server and modeled using 
the GROMOS force field for post-translational modifications. Water molecules and ions were 
added to achieve an ionic strength of 0.1 M. All bonds were constrained using the LINCS 
algorithm, and production runs were carried out with no restraints under the NPT ensemble with 
the GROMACS 5.0.6 simulation software. Analyses were performed with VMD and GROMACS 
utilities and in-house tools and scripts in python, C++ and FORTRAN. We performed short runs 
of native and pY240-PTEN to prepare the structures for blind and directed docking. The latest 
frame of the pY240-PTEN trajectory (Figure S4E), with an accessible phosphatase pocket, was 
used as a starting point for simulations with the Ki-67 peptide, which was placed randomly 
around the PTEN surface in three different orientations. In one of the trajectories Ki-67 docked 
VSRQWDQHRXVO\LQWKHFRQVHUYHGELQGLQJSRFNHWVVKDUHGE\37(1DQG33ȖIRUPLQJDVWDEOH
complex. Ki-67 was also docked upon alignment of the structurally conserved pocket using the 
X-UD\33ȖFRPSOH[DVUHIHUHQFH7KHUHVXOWLQJS<-PTEN-Ki-67 complex was also subject 
to simulations to evaluate its stability. The energies of the Ki-67 complexes with pY240-PTEN 
and PP1Ȗ were evaluated with the webserver PRODIGY (PROtein binDIng enerGY prediction). 
Total simulated time was 5 microseconds (Table S5). 
Quantification and Statistical Analysis 
 All statistical analyses, unless specified elsewhere, were performed using GraphPad Prism 6 
software. The specific test used for each experiment to determine significance (* p<0.05) is 
indicated in the text of the results and/or figure legends. Data are representative of results 
obtained in at least 3 independent experiments.  
For mass spectrum analysis, the MS raw files were processed by Sorcerer-SEQUEST using the 
reviewed Swiss-prot human database. The identified peptides were quantified using XPRESS 
and a minimal ion intensity of 1X103 was used to calculate the abundance ratio. 
Data and Software Availability 
Mass Spectrometry data have been deposited to UCSD MassIVE Repository, accessible 
through the link http://massive.ucsd.edu/ProteoSAFe  with ID # PXD007212    
 
Movie S1. Blind simulation of the interaction of Ki-67 and PTEN. Related to Figure 5. 
 
The latest frame of the pY240 PTEN trajectory was used as a starting point for blind docking 
simulations with the Ki-67 peptide (containing RVxF, ))and KiR-SLiM motifs), which was 
placed randomly around the PTEN surface in three different orientations. Ki-67 peptide (the 
smaller moving object above) spontaneously tumbled and docked with the hydrophobic pockets 
of PTEN (the bigger object below) forming a complex that remained stable in subsequent 
simulations. 
  
 Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
pY240-PTEN mouse monoclonal antibody This paper, by GeneScript  N/A 
pY240-PTEN rabbit monoclonal antibody This paper, by ABclonal  N/A 
PTEN (N19) antibody Santa Cruz Biotechnology RRID: AB_654895 
PTEN (A2B1) antibody, Santa Cruz Biotechnology RRID: AB_628187 
Rabbit Anti-Human Ki-67 (H-300) Polyclonal Santa Cruz Biotechnology RRID: AB_2250495 
RAD51 (H-92) antibody Santa Cruz Biotechnology RRID: AB_2253533 
Bek (C-17) (FGFR2) antibody Santa Cruz Biotechnology RRID: AB_631509 
Ki-67 antibody (H300) Santa Cruz Biotechnology RRID: AB_2250495 
RPA 32 kDa subunit Antibody (H-100) Santa Cruz Biotechnology RRID: AB_2238546 
Histone H3 (D2B12) XP Rabbit mAb (ChIP Formulated)  Cell Signaling Technology RRID: AB_1904005 
Tri-Methyl-Histone H3 (Lys9) Antibody Cell Signaling Technology RRID: AB_2561049 
Rabbit Anti-ATM Monoclonal Antibody, Clone D2E2 Cell Signaling Technology RRID: AB_2062659 
Lamin A/C Antibody Cell Signaling Technology RRID: AB_2136278 
Phospho-ATM (Ser1981) (D6H9) Rabbit mAb antibody Cell Signaling Technology RRID: AB_10835213 
Rabbit Anti-GAPDH Monoclonal Antibody Cell Signaling Technology RRID: AB_561053 
Phospho-ATR (Ser428) Antibody Cell Signaling Technology RRID: AB_10120986 
Anti-ATR Antibody Cell Signaling Technology RRID: AB_2227860 
Phospho-Chk2 (Thr68) (C13C1) Rabbit mAb antibody Cell Signaling Technology RRID: AB_2244927 
Chk2 (D9C6) XP Rabbit mAb antibody Cell Signaling Technology RRID: AB_11178526 
Rabbit Anti-ETubulin Monoclonal Antibody, Clone 9F3 Cell Signaling Technology RRID: AB_823664 
Nucleolin Antibody Cell Signaling Technology Cat # 12247 
Phospho-EGF Receptor (Tyr1068) Cell Signaling Technology RRID: AB_2096270 
EGF Receptor (D38B1) XP Rabbit mAb Cell Signaling Technology RRID: AB_2246311 
AKT Antibody Cell Signaling Technology RRID: AB_329827 
Phospho-AKT (Ser473) (193H12) Rabbit mAb Cell Signaling Technology RRID: AB_331168 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)  Cell Signaling Technology RRID: AB_331772 
Phospho-S6 Ribosomal Protein (Ser235/236) Cell Signaling Technology RRID: AB_916156 
SUMO-2/3 (18H8) Rabbit mAb antibody Cell Signaling Technology RRID: AB_2198425 
HDAC2 Cell Signaling Technology RRID: AB_2116822 
MEK1/2 Cell Signaling Technology RRID: AB_10829473 
Na/K ATPase antibody EP1845Y Abcam RRID: AB_1310695 
Monoclonal Anti-ȕ-$FWLQí3HUR[LGDVHDQWLERG\ Sigma-Aldrich RRID: AB_262011 
Vimentin Sigma-Aldrich RRID: AB_609914 
Anti-phospho-Histone H2A.X (Ser139), clone JBW301 Millipore RRID: AB_309864 
Anti-Phosphotyrosine, clone 4G10 Millipore RRID: AB_310776 
Monoclonal Anti-Human PTEN (clone 6H2.1) Cascade Bioscience Cat # ABM-2052 
mNeonGreen antibody (32F6) ChromoTek GmbH Cat # 32f6-100 
Bacterial and Virus Strains 
Biological Samples   
GBM patients sample sections University of California, LA  
Chemicals, Peptides, and Recombinant Proteins 
AZD4547 Selleck Chemicals Cat # S2801 
PD173074 Selleck Chemicals Cat # S1204 
Erlotinib Selleck Chemicals Cat# S1023 
 Doxorubicin Sigma-Aldrich Cat# D1515  
Active, N-terminal, His6-tagged, recombinant, human 
FGFR2, amino acids 456-770 
Millipore Cat # 14-617 
Active, N-Terminal His6-tagged, recombinant, full-
length, human Src 
Millipore Cat # 14-326M 
pGEX-4T3 GST-PTEN WT recombinant protein By Dr. Tim R. Fenton N/A 
pGEX-4T3 GST-PTEN Y240 recombinant protein By Dr. Tim R. Fenton N/A 
Peptide for pY240-PTEN mouse monoclonal antibody: 
CTRREDKFMpYFEFPQ 
This paper Custom synthesis by 
GenScript 
Ki-67 WT peptide around KiR-SLIM: 
ELFDENLPPNTPLKRGEAPTK 
This paper Custom synthesis by 
ThermoFisherScientific 
Ki-67 mutant peptide around KiR-SLIM: 
ELFRKNLPPNTPLDEGKAPTE 
This paper Custom synthesis by 
ThermoFisherScientific 
Pulsin kit for peptide transfection Polyplus-transfection Cat # 501-04 
Critical Commercial Assays 
CometAssay Reagent kit Trevigen Cat # 4250-050-K 
Subcellular Protein Fractionation Kit for Cultured Cells ThermoFisher Scientific Cat# 78840 
Deposited Data 






Experimental Models: Cell Lines 
U87  ATCC RRID: CVCL_0022 
HEK293T cell line ATCC RRID: CVCL_0063 
TS528 Cameron Brennan N/A 
TS543 Cameron Brennan N/A 
TS576 Cameron Brennan N/A 
TS600 Cameron Brennan N/A 
HK281 University of California, LA N/A 
GSC11 MD Anderson  N/A 
GSC23 MD Anderson N/A 
GBM6 Northwestern University N/A 
GBM39 Northwestern University N/A 
GBM1600 Ludwig Institute N/A 
Experimental Models: Organisms/Strains 
C57BL/6J mice Jackson Laboratory Cat # 000664 
E2a-cre mice Jackson Laboratory Cat # 003314 
FVB.129-Cdkn2atm1Rdp (Ink4aArf-null) mice NCI repository Cat # 01XB2 
NU/NU Nude Mouse Charles River Strain code: 088 
Biological Samples   
Human GBM IHC slides University of São Paulo  
Oligonucleotides 
Silencer® Select Negative Control No. 1 siRNA ThermoFisher Scientific Cat # 4390843 
Silencer® Select siRNA MKI67 s54543 ThermoFisher Scientific Cat # 4392420 
Silencer® Select siRNA MKI67 s8797 ThermoFisher Scientific Cat # 4392420 
 *HQRW\SLQJSULPHU¶ 
CAGATCCTCAGTTTGTGGTCT 




This paper Custom synthesis by 
IDT 
Recombinant DNA 
pLV-EF1a-MCS-IRES-Puro plasmid BioSettia cDNA-pLV01 
Ki-67- mNeonGreen constructs (1-7) Dr. Daniel W. Gerlich N/A 
Ki-67-mNeonGreen truncation 8 This paper 485-565: 81aa N/A 
pLV-Flag-PTEN constructs This paper N/A 
pLV-FGFR2 constructs This paper N/A 
Software and Algorithms 
ELDA analysis software http://bioinf.wehi.edu.au/s
oftware/elda 
 
CometAssay software Trevigen  
Swiss-prot human database http://www.uniprot.org/  




















Table S1, related to Figure 1. 
 
Case # WHO gradea Ageb Genderc Tumor locationd KPSe GBM subtype 
74 IV 74 M L frontal, parietal 40% classic 
194 IV 71 M L parietal, temporal 80% classic 
216 IV 67 F L parietal, occipital 40% not determined 
269 IV 65 F R frontal ND classic 
317 IV 71 F R temporal 50% not determined 
356 IV 74 M R frontal, temporal, insula 70% classic 
384 IV 45 M R parietal, temporal, midbrain 50% not determined 
391 IV 54 F R parietal, temporal 50% mesenchymal 
397 IV 58 F L parietal, frontal 90% R132H - proneural 
435 IV 34 M L parietal, frontal 50% not determined 
442 IV 68 M R frontal, temporal, parietal 50% not determined 
485 IV 67 M R parietal, temporal 60% classic 
496 IV 57 F R parietal, temporal 70% classic 
498 IV 17 F R frontal, parietal, temporal 30% classic 
510 IV 56 M R parietal 50% not determined 
522 IV 48 M L temporal 100% R132H - proneural 
592 IV 45 M L parietal, frontal 80% proneural 
1103 IV 54 M  ND mesenchymal 




 non-neoplastic; II, low-grade astrocytoma; III, anaplastic astrocytoma; IV, glioblastoma (GBM).  
b
, Age at diagnosis was calculated from date of birth to date of surgery.   
c
, M, Male; F, Female.   
d
, L, Left; R, Right.   
e
, Karnowsky Performance Status. Patients are classified according to their functional impairment level, where 






























GSC295 6.9 15.3 15.3 15.3   Sensitive 
GSC2 6.3 8.9 8.9 8.9   Resistant 
GS10-6 6.2 10.9 10.9 10.9   Resistant 
GSC296 5.8 14.1 14.1 14.1   Resistant 
GS5-22 5.7 11.5 11.5 11.5   Sensitive 
GSC112 4.7 6.9 6.9 6.9   Sensitive 
GS4-16 4.7 11.0 11.0 11.0   Resistant 
GS3-25 4.6 7.8 7.8 7.8   intermediate 
GSC304 4.5 12.4 12.4 12.4   Resistant 
GSC300 4.0 10.6 10.6 10.6   Resistant 
GS7-2 3.7 15.8 15.8 15.8   Resistant 
GSC264 3.6 17.7 17.7 17.7   intermediate 
GS7-11 3.4 4.2 4.2 4.2 Missense I33F Sensitive 
GSC107 3.4 5.9 5.9 5.9   Resistant 
GS7-10 3.2 6.4 6.4 6.4 Missense Y68H intermediate 
GSC289 3.1 17.8 17.8 17.8   intermediate 
GSC293 3.0 6.1 6.1 6.1   Sensitive 
GSC280 2.9 6.9 6.9 6.9 Splice Site  intermediate 
GSC34 2.8 11.2 11.2 11.2   Resistant 
GSC16 2.6 5.5 5.5 5.5   intermediate 
GSC275 2.4 8.4 8.4 8.4 Missense D22G intermediate 
GSC17 2.4 0.1 0.1 0.1 In Frame del del198M Resistant 
GSC240 2.4 6.0 6.0 6.0   intermediate 
GSC248 2.3 10.5 10.5 10.5   intermediate 
GS4-23 2.3 13.4 13.4 13.4 Missense M134I Sensitive 
GSC272 2.2 5.7 5.7 5.7   Sensitive 
GS8-18 2.1 10.4 10.4 10.4   Sensitive 
GSC268 2.0 6.8 6.8 6.8   Resistant 
GSC28 1.9 8.4 8.4 8.4   Sensitive 
GS8-11 1.8 2.2 2.2 2.2   Sensitive 
GS7-15 1.7 6.9 6.9 6.9   Resistant 
GS2-14 1.7 4.9 4.9 4.9   Sensitive 
GSC20 1.2 7.2 7.2 7.2   Sensitive 
GSC231 1.2 9.5 9.5 9.5   Sensitive 
GSC262 1.1 10.1 10.1 10.1   Sensitive 
GSC23 0.6 16.4 16.4 16.4   Resistant 
GS3-28 0.4 6.6 6.6 6.6   Resistant 
GSC11 0.2 16.7 16.7 16.7   Resistant 
GSC285 0.0 9.8 9.8 9.8   intermediate 
GS6-27 0.0 8.4 8.4 8.4   Resistant 
GSC282 0.0 7.5 7.5 7.5   Sensitive 
GSC236 0.0 10.7 10.7 10.7   Sensitive 
GSC267 0.0 14.3 14.3 14.3   Sensitive 
GSC274 0.0 3.8 3.8 3.8   Sensitive 
 
Bold line indicated the median expression value of PTEN (2.5) for all cell lines in this RNAseq experiment based on 





Table S3, related to all Figures with cell data. 
 
Cells FGFR2 PTEN wild-type PTEN Y240F Heter_expr 
U87 Not detectable - - FGFR2, WT-or YF-PTEN 
HK281 + - - WT-or YF-PTEN  
    Endogenous 
TS528 + + - FGFR2, WT-PTEN 
GBM patient-derived cells + + - FGFR2, WT-PTEN 
Mouse WT primary 
spheres 
+ + - FGFR2, WT-PTEN 
Mouse YF primary 
spheres 
+ - + FGFR2, YF-PTEN 













Figure S1, related to Figure 1  
(A) In vitro kinase assay was performed by incubating recombinant FGFR2 with recombinant purified GST-PTEN 
(WT and Y240F (YF)), followed by probing with anti-pY240-PTEN antibody and PTEN antibody. (B) Three 
representative cells from radiation sensitive or resistant group (Figure 1D) were analyzed for PTEN expression and 
localization. Left panel represents PTEN expression level in whole cell lysates; right panel indicates equal cell 
equivalents of nuclear (N) and cytoplasm (C) fractions from these cells immunoblotted for PTEN and FGFR2. R1-3, 
3 radiation resistant cells; S1-3, 3 radiation sensitive cells. (C) U87 cells transfected with FGFR2 or empty vector 
(V) along with WT-or YF-PTEN were blotted for the presence of pY240-PTEN. (D) Colony numbers from WT-, 
YF-PTEN cells and vector control (V) cells after treatment with 10 Gy irradiation. (E) Bar graph shows colony 
numbers of different treatment groups in the absence of FGFR2. (F) Images show comet assay for U87 cells 
reconstituted with empty vector (V), WT- or YF-PTEN in the absence of FGFR2. Bar graph at right shows 
quantification of tail moment. Scale bar, 500 µm. (G) Wild type (WT) or kinase dead (KD) FGFR2 was 
overexpressed in U87 cells reconstituted with WT-or YF-PTEN. Cells were treated with 10 Gy IR and pH2AX was 
examined at indicated times. Numbers at the bottom indicate ratio of pH2AX levels relative to time 0 after 
normalization to actin, calculated as mean ± SD from three independent experiments, *p<0.05 was generated by 
comparing WT- and YF-PTEN samples at the same time point. (H) U2OS cells CRISPR/Cas9 edited for PTEN or 
U87 cells were reconstituted with empty vector (V), WT- or YF-PTEN along with FGFR2 (left top). DNA repair 
efficiency using traffic light assay was determined by flow cytometry, with percentage of GFP-positive cells 
indicating HR efficiency and mCherry-positive cells indicating NHEJ efficiency. Representative flow plots are 
shown (bottom) and bar graph indicating quantification of flow cytometry data (right top). NC, negative control, 
where no DNA damage was induced by I-SceI. (I) WT- or YF-PTEN U87 cells were treated with 10 Gy IR and 
RPA32 foci were detected at indicated times by immunostaining. Representative images and quantification of foci 
positive cells are shown. Scale bar, 25 µm. (J) Cells treated and analyzed the same as (I) for BrdU foci. Scale bar, 








Table S4, related to Figure 2. 
Name Source Cell type In vitro growth In vivo growth FGFR2  PTEN  
GBM 39 David James 
UCSF 
Neurosphere 
(GBM xenograft) moderate moderate - + 
GBM 6 David James 
UCSF 
Neurosphere 






fast   - + 
HK 281 Dr. Kornblum 
UCLA 
Human 
neurosphere fast  fast + - 
GSC 11 Fred Lang, MD 
Anderson 
Glioma stem cell 
fast   - - 
GSC 23 Fred Lang, MD 
Anderson 
 
fast   + - 
TS528 Dr. Brennan 
MSKCC 
Glioma stem cell 
fast   + + 
TS543 Dr. Brennan 
MSKCC 
Glioma stem cell 
fast fast - + 
TS576 Dr. Brennan 
MSKCC 
Glioma stem cell 
fast fast - + 
TS600 Dr. Brennan 
MSKCC 
Glioma stem cell 
fast moderate - - 
GSC2 Erik Sulman  
MD Anderson 
Glioma stem cell 
moderate moderate + + 
GS10-6 Erik Sulman  
MD Anderson 
Glioma stem cell 












Figure S2, related to Figure 3 
(A) U87 cells reconstituted with WT-PTEN along with FGFR2 were treated with IR (10 Gy) and then examined for 
PTEN subcellular localization by western blot. WCL, whole cell lysates, C, cytoplasm, N, nuclear, M, membrane, 
CK, cytoskeleton.  (B) Cells lysates from (A) were prepared followed by immunoprecipitation with anti-FGFR2 
antibody and western blot examination of phosphorylation of FGFR2 (Tyr653/654) in IP products and phosphor-
ERK in whole cell lysates. (C) cytoplasm (C) and nuclear fractions (N) were prepared and were examined for 
FGFR2. Long expo, longer exposure time. (D) Cell cycle profiles were examined from U87 cells (left) or HK281 
cells (right) reconstituted with V or WT- or YF-PTEN along with FGFR2 after IR treatment at the indicated times. 
(E) Micrococcal nuclease assay was performed using U87cells reconstituted with WT- or YF-PTEN along with 
FGFR2 after IR treatment at the indicated times. N, non-IR control. (F) Cells were treated with or without IR at 10 
Gy, cell lysates were prepared followed by immunoprecipitation with anti-PTEN antibody. SUMOylation was 
evaluated by anti-SUMO 2/3 antibody and PTEN-HRP antibody. Long expo, longer exposure time; short expo, 
shorter exposure time. (G) 293T cells transfected with Flag-tagged WT- or YF- or K254R (KR)-PTEN along with 






Figure S3, related to Figure 4  
(A) U87 cells reconstituted with WT-, YF- or C124S (CS)-PTEN were examined for phosphorylation of Y240 
PTEN by western blot. (B) Cells from (A) were treated with 10 Gy IR and analyzed for pH2AX at indicated times. 
(C) U87 cells reconstituted with WT-, YF- or GR-PTEN were treated with 10 Gy IR and were analyzed for colony 
formation, and representative images are shown. (D) Colony size was determined by Keyence software and graphed 
as shown. ns, not significant; Data represent mean ± SD from three independent experiments. *p < 0.05. (E) U87 
cells reconstituted with WT-, GR-PTEN along with FGFR2 were treated with 10 Gy IR and chromatin-bound 











Figure S4, related to Figure 5 
 
 (A) The binding pocket for the KiR-SLiM of PP1J and PTEN showed high 3D structure similarity (<2.5Å) 
according to different structural alignment methods (CLICK, SPalign, RaptorX, mTM-align) according to different 
structural alignment methods (CLICK, SPalign, RaptorX, mTM-align) (Brown et al., 2016; Dong et al., 2018; 
Nguyen et al., 2011; Wang et al., 2013).  All methods identified a helix motif (B) with a 11-mer sequence of 
chemically-conserved positions highlighted with a box (C), along with two neighboring beta-sheets, which together 
form the binding site for Ki-67. Note the identically charged residues in (B). (D) Pose illustrating close-up view of 
the PP1J(PDB entry: 5J28) -Ki-67 interaction. Compared with the interaction of pY240-PTEN (Figure 5I), the KiR-
SLiM sequence is flipped but retains key asparagines and other polar/charged residues in similar positions within the 
binding cleft. (E) Comparison of simulations of native (grey) and pY240-PTEN (red) show that phosphorylation 
favors the closure of the isoprenoid binding cleft (above) and increases the accessibility of the PD binding pocket 
(below). (F) Close-up view of the TYR240 phosphorylation site. While TYR240 forms stable H-bonds with 
GLU235 and ARG233 in native PTEN, upon phosphorylation these contacts are broken and substituted by 
interactions between the negatively charged pTYR240 with LYS197 and ARG233 (right). (G) Multiple short 
unbiased trajectories in which the Ki-67 fragment was randomly placed around pY240-PTEN were run and then Ki-
67 was directly docked in a similar pose as that observed for its interaction with PP1J. To prepare the pY240-PTEN 
structure, short MD runs were performed using the unphosphorylated protein as control. Average distance between 
Ki-67 and the PD binding pockets seen in different replica trajectories for blind docking; The trajectory in red 
corresponds to the spontaneous binding event of Ki-67 to conserved phosphatase domain pocket shown in Figure 
5H, 5I. (H) Comparison of the X-ray guided Ki-67 docking pose (red) with the spontaneous MD complex (orange) 
at 0 and 400 ns time; note how the KiR-SLiM sequence docked as in the crystal tends to reorient acquiring a similar 
arrangement as in the simulation complex. (I) Ki-67 truncations 6, 7 and 8 (Figure 5G) was co-transfected with 
PTEN in 293T cells followed by IP with mNeonGreen nAb and western blotted with mNeonGreen (mG) and PTEN 
antibody (left panel). Representative images showing the localization of truncations 6, 7 and 8 (right panel). Scale 
bar, 50 µm. (J) Rescue experiment was performed by expressing Ki-67 truncation 6 and 7 (Figure 5G) in U87-GR-
PTEN cells knocked down for Ki-67 (siRNA-2) expression. PTEN chromatin loading was detected by western blot. 
NC, si-scramble, non-specific control. (K) WT and mutant Ki-67 peptides containing the KiR-SLiM motif were 
synthesized. (L) GR-PTEN U87 cells transfected with control peptide (R-phycoerythrin, with red fluorescence) 
alone, or together with Ki-67 peptides (WT or mutant) at 1:5 ratio. Representative pictures indicate the transfection 
efficiency (left panel). Cell lysates were collected 6 hr after transfection and co-immunoprecipitation was performed 
using Ki-67 antibody. Western blot (right panel) showed WT peptide transfection decreased PTEN and Ki-67 
interaction. wt, wild type Ki-67 peptide; mut, mutant Ki-67 peptide. Scale bar, 500 µm (M) U87 cells reconstituted 
with WT-PTEN along with FGFR2 were transfected with control, WT or mutant Ki-67 peptides followed by IR 
(10Gy) treatment. pH2AX was examined at indicated times after IR. (N) U87-GR-PTEN cells were transfected with 
increasing amount of PP1Jand cell lysates were used to perform co-immunoprecipitation using Ki-67 antibody 
(right). Chromatin binding of PTEN and PP1Jand interaction between Ki-67 and PTEN or PP1Jwere evaluated by 





Table S5, related to Figure 5 
 
Simulations Starting conformation Time (ns) Observed events 
PTEN phosphorylation Native PTEN 250 
 
Hinge-bending motions of the PD and 
C2 domains 
 pY240-PTEN 950 Increased motions with closure of the 
PD / C2 catalytic cleft 
PTEN-KI-67 interaction 
(Blind docking) 





Tumbling and docking to PD pockets 
Weak lateral interactions 
Increasing separation 
 Orientation 2 250  Weak lateral interactions 
 Orientation 3 175 Weak lateral interactions 




Stable binding through KiR-SLiM 
Stable binding through KiR-SLiM 
 X-ray guided complex (2X) 400 
425 
Reorientation to blind-docking pose 







Figure S5, related to Figure 6.                                         
(A) Schematic representation of Cdkn2a null; Y240F Pten knock-in strategy. Box E6, E7, E8, E9 represent Pten 
exons. pGK-Neo-2.5K denotes neomycin resistance selection cassette. Y240F point mutation and Hind III 
restriction site adjacent to E7 were introduced by PCR in the targeting vector. (B) Southern analysis of ES cell 
clones. Hind III-digested genomic DNA was hybridized with probe 3. *Indicates correctly targeted clones, which 
show the presence of an 8.2 Kb fragment, while 9.5 Kb indicates non-targeted events. (C) Genotyping PCR 
reactions were performed using tail DNA followed by RsaI digestion. WT mice showed a single band of 300 bp, 
while mice with the Y240F knock-in allele displayed a 400 bp product (loss of RsaI restriction site present in WT 
allele). Genotyping results were ultimately confirmed by sequencing (right). (D) Mouse embryo fibroblasts (MEFs) 
were prepared from E12.5 WT and Y240F embryos as described (Durkin et al., 2013). Cells were serum starved for 
16 hours followed by treatment with EGF, EGF+ 5 PM Erlotinib (EGFR inhibitor) or 10% FBS stimulation. Cell 
lysates were collected 30 min after stimulation and AKT and EGFR-MAPK/ERK pathways activation were 
examined. S, serum starvation; EGF, 10 ng/mL; +Er, EGF plus 5 PM Erlotinib; +ser, stimulated with 10%FBS. (E) 
Primary neurospheres were prepared as described and PTEN lipid phosphatase activity was compared between WT 













Figure S6, related to Figure 7. 
(A)  GSC2 and GS 10-6 cells were treated with or without FGFR inhibitor, AZD4547 (1 µM), for 16 hr and then 
irradiated at 5 Gy. Cell lysates were prepared for detection of pH2AX by western blot. (B) GS 10-6 cells, pre-treated 
with or without AZD4547, were irradiated at 5 Gy and were analyzed for survival by limiting dilution assay. (C) 
GSC2 cells were treated and analyzed as (B). (D) GSC2 cells (0.5x106) were intracranially injected into 
immunodeficient mice and after tumor establishment mice were administrated AZD4547 by gavage combined with 
IR for three cycles starting from day 14 after post engraftment (see Figure 7B). Representative images taken at day 
18 are shown. (E) Kaplan-Meier analysis of mice survival are shown. Ctrl, treated with vehicle; FGFRi, treated with 
50 mg/Kg AZD4547; IR, treated with 2.5 Gy IR; FGFRi (2 hr)-IR, treated with 2.5 Gy IR after 2 hr of AZD 
treatment; FGFRi (4 hr)-IR, treated with 2.5 Gy IR after 4 hr of AZD treatment. (F) As in Figure 7B-F, 
immunodeficient mice (nu/nu), from the same vendor as Figure 7, were subjected to IR treatment four hours after 
AZD4547 administration for 3 consecutive days. Representative images show H&E staining of sections from major 
organs 24 hr after last treatment, including intestine, colon, brain, kidney and liver. C, non-treated; T, treated. Scale 
bar, 200 µm. (G) WT- and YF- Pten knock-in mice (C57BL/6J) were treated with IR 4 hr after AZD4547 
administration for 3 consecutive days. Representative images show H&E staining of sections from major organs 24 
hr after treatment, including intestine, colon, brain, kidney and liver. Scale bar, 200 µm. (H) Body weight change of 
mice from (F) was monitored after treatment over time up to 36 days. (I) Immunodeficient mice were orthotopically 
injected with HK281-WT-PTEN cells (2.0x105 cells per mouse). Tumor formed two weeks after injection as 
monitored by FMT signal. Mice with tumors were treated with IR four hours after AZD4547 administration for 3 
consecutive days. Brains were collected 24 hr after treatment followed by TUNEL staining. Bar graph indicates 
quantification of TUNEL positive cells in tumor area and surrounding normal brain. Scale bar, 100 µm. Error bars 









Figure S7, related to Figure 7. 
 (A) U87 cells reconstituted with WT or Y240F PTEN along with FGFR2 were treated with 0.5 PM doxorubicin 
(Dox) or 50 PM temozolomide (TMZ) for the indicated time. pH2AX was detected by western blot analysis. (B) 
GBM39, a patient-derived EGFRvIII-expressing xenograft model, was treated with 5 PM EGFR inhibitor, Erlotinib, 
for the indicated times. (C) U87 cells reconstituted with WT- or YF-PTEN along with EGFRvIII were treated with 5 
PM Erlotinib for the indicated time. pH2AX was detected by immunoblot analysis. (D) HK281 cells reconstituted 
with WT-, YF-, GR-, or Y240F/G129R (GR/YF)-PTEN were stably labeled with RFP, BFP, GFP and GFP, 
respectively, and were mixed in equal ratios as shown. Mixtures were divided into two cultures with one of them 
being treated with 3 cycles of 5 Gy IR. Cell mixtures were then allowed to grow for 10 days and analyzed by flow 
cytometry to determine changes in abundance of each cell population. All quantification data represent mean ± SD 
from three independent experiments. *p < 0.05. 
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